Regenerative medicine approach in orthopaedic surgery by Canseco, José Antoni
Tissue Engineering the Anterior Cruciate Ligament: A Regenerative
Medicine Approach in Orthopaedic Surgery
By
Jose Antonio Canseco
B.S. Bioengineering
Rice University, 2003
SUBMITTED TO THE HARVARD-MIT DIVISION OF HEALTH SCIENCES AND
TECHNOLOGY IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE
DEGREE OF
DOCTOR OF PHILOSOPHY IN BIOMEDICAL ENGINEERING
AT THE
MASSACHUSETTS INSTITUTE OF TECHNOLOGY
JUNE 2013
0 2013 Massachusetts Institute of Technology. All rights reserved.
MASSACHUSETTS INSTITUTE
OF TECHNOLOG Y
AUG 0 1 2013
LIBRARIES
Signature of Author ............................................ - - . .. .... ... .. ... . .. ... . .. .. .. ...
Jos6 Antonio Canseco
Harvard-MIT Division of Hea h Sciences & Technology
May 10th, 2013
Certified by .................... 
- - v 
--- 
-Charles Alfred Vaci1 ti, MD
Vandan/Covino Professor of Anaesthesia, Harvard Medical School
Chairman, Department of Anesthesiology, Perioperative and Pain Medicine
Director, Laboratory for Tissue Engineering and Regenerative Medicine
Brigham and Women's Hospital
Thesis Supervisor
A ccepted by ......... ........................................
Emery Neal Brown, MD PhD
Director, Harvard-MIT Division of Health Sciences and Technology
Warren M. Zapol Professor of Anaesthesia, Harvard Medical School and Massachusetts General Hospital
Professor of Computational Neuroscience and Health Sciences and Technology
Massachusetts Institute of Technology
I

Tissue Engineering the Anterior Cruciate Ligament: A Regenerative
Medicine Approach in Orthopaedic Surgery
By
Jos6 Antonio Canseco
Submitted to the Harvard-MIT Division of Health Sciences and Technology
on May 10th, 2013 in Partial Fulfillment of the Requirements for the Degree of
Doctor of Philosophy in Biomedical Engineering
Abstract
Anterior cruciate ligament (ACL) injuries affect over 200,000 Americans yearly, and many occur
in young athletes. Current treatment options include tendon autografts and cadaveric allografts.
However, these approaches often lead to secondary medical problems, such as donor-site
morbidity and immune rejection. Furthermore, in younger patients these grafts fail to grow,
leading to additional complications and underlining the need for the development of new
approaches that improve the healing and repair of ligaments and tendons. This thesis aims to
develop a technique to engineer ACL from autologous mesenchymal stem cells (MSC) and
primary ACL fibroblasts using the basic principles of Tissue Engineering. The first part of the
thesis characterizes MSCs isolated from tibial bone marrow as an alternative to hip-derived
marrow aspirates. The proximity of the tibia to the surgical site of ACL reconstructions makes it
a viable source of marrow derived-MSCs for ligament repair, with less stress for the patient and
increased flexibility in the operating room. Characterization was performed by fluorescence-
activated cell sorting for MSC-surface markers, and assays to differentiate MSCs towards
adipogenic, osteogenic and chondrogenic lineages. The second part of the thesis describes the
effects of in vitro co-cultures of ACL fibroblast and MSC on the expression of ligament-
associated markers. The goal was to optimize the cell-cell ratio in order to maximize the positive
effects of co-cultures on ligament regeneration. Co-cultures of ACL fibroblasts and MSCs were
studied for 14 and 28 days in vitro, and the effects assessed with quantitative mRNA expression
and immunofluorescence of ligament markers Collagen type I, Collagen type III and Tenascin-C.
Finally, based on the enhancing effect observed in co-cultures, the thesis explores a method to
regenerate ACL using a three-dimensional polyglyconate scaffold seeded with cell-hydrogel
suspensions containing ACL fibroblasts and MSCs. Constructs were analyzed biochemically and
by immunofluorescence after 4 weeks in culture with and without mechanical stimulation.
Together, our results establish an experimental framework from which a new technique for ACL
repair can be developed. The ultimate goal is to foster the design of a one-stage surgical
procedure for improved primary ACL augmentation repair that can soon be translated into
clinical practice.
Thesis Supervisor: Charles Alfred Vacanti, MD
Title: Vandam/Covino Professor of Anaesthesia, Harvard Medical School; Director, Laboratory
for Tissue Engineering and Regenerative Medicine, Brigham and Women's Hospital
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Chapter 1.
The Anterior Cruciate Ligament and Our Approach for Potential
Primary ACL Augmentation Repair
1.1. Anatomy and Physiology
L igaments and tendons are dense connective tissues that have the function to providest bility and support connections within the musculoskeletal system. Ligaments provide
connections between bones, while tendons connect muscles to bones. The anterior cruciate
ligament (ACL) is an extrasynovial structure located inside the knee joint (1). Within the knee
joint, the ligament at the proximal end is attached to the posteromedial fossa of the lateral
femoral condyle, while distally it attaches to the tibial plateau at the anterior intercondylar fossa
(1) (Figure 1.1).
Structurally, the ACL is comprised of two bundles, the anteromedial and the
posterolateral bundles (2). These bundles are composed of fascicles made of collagen fibers,
glycosaminoglycans and cells (2). Approximately 94% of a fascicle is made out of collagen, with
a 9:1 composition ratio of collagen type I to collagen type III, and minimal content of collagen
types II, IV and VI (2-4); the remaining 6% includes various proteoglycans, glycosaminoglycans
and ligament fibroblasts (2).
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The middle geniculate artery, medial
inferior geniculate artery and lateral inferior
geniculate artery provide a limited blood supply to
the ACL (1,5,6). Some scientists have
hypothesized that part of the reason the ACL has a
limited ability to self-heal is the scarcity of its
blood supply (7). The ACL is a well innervated d 4
structure, with most of the nerves provided by the
posterior articular branches of the tibial nerve (1).
An important feature of ACL innervation is its
heavy supply of mechanoreceptors for
proprioception, including Ruffini corpuscles, Golgi
tendon organs, Pacinian corpuscles and various 0
nociceptors (1). These features suggest that the
ACL is a highly sensitive structure with an
important role in detecting and relaying joint
position (1,8). Furthermore, some researchers
suggest ACL nerves may trigger muscle reflexes
that can protect and stabilize the knee during
motion (9). These neural properties of ACL, along
with possible improvement in graft vascularization, Figure 1.1. Knee joint anatomy. Image from
suggest that future therapies should explore Gray's Anatomy, 1918.
sparing ACL remnants during reconstruction
and/or repair (9-11).
The primary function of a ligament is the transmission of tensional forces between bones
to maintain uniform joint motion and avoid abnormal joint displacements (12). Physiologically,
the ACL functions to prevent excessive anterior translation of the tibia and maintains rotational
joint stability (13). The ACL is also important in preventing medial displacement of the tibia
(14,15). More specifically, each bundle of the ACL plays a unique biomechanical role depending
on joint position, with the anteromedial bundle carrying greater loads during knee flexion, and
the posterolateral bundle playing a more prominent role during knee extension (9,16).
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1.2. Injuries and Healing
Injury to the ACL represents one of the most common athletic injuries and the most
common ligament injury involving the knee joint (17,18). The literature estimates that close to
200,000 ACL injuries occur yearly in the United States (9). Approximately a third of ACL
injuries are caused by contact, where a planted lower leg receives an externally applied torque
leading to rupture (19). Non-contact ACL injuries account for over two-thirds of all injuries; in
these cases a sudden leg deceleration causes a tear when there is simultaneous quadriceps
contraction and full knee extension (19), or when the deceleration leads to an excessive valgus
load of the knee joint (20). In the United States, more than 100,000 ACL reconstructions are
done each year (18,21,22). In fact, the literature reports that the incidence of ACL injuries is
close to 1 in 3500 knee injuries, with the majority of patients electing surgical reconstruction for
repair (23,24).
As studied by Woo and colleagues in medial collateral ligament (MCL) samples, it is
generally agreed that following injury, ligament healing follows the same three overlapping
stages of other soft-tissue healing responses: [1] the hemorrhagic/inflammatory phase, where
bleeding occurs at the site of ligament rupture forming a clot that over a period of around 2
weeks transforms from granulation tissue into an immature collagen matrix, thanks in part to the
migration and activity of inflammatory cells; [2] the proliferative/reparative phase is
characterized by the migration of fibroblasts to the site and the initial deposition of a
disorganized extra-cellular matrix; and [3] the remodeling/maturation phase, where the collagen
and extra-cellular matrix undergoes reorganization and realignment towards the load-bearing
axis of the tissue (7,12,22).
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Figure 1.2. Right ACL tear. Image from MayoClinic.com article "ACL Injury", with
permission. Courtesy of 0 Mayo Foundation for Medical Education and Research. All
rights reserved.
It is important to note that in contrast to most ligaments and tendons in the human body,
the ACL is characterized by an inability to successfully self-heal after injury. Because of the
ACL's limited blood supply, some investigators have postulated that its observed poor healing
capacity stems in part from an inability to supply the injury site with sufficient resources for
healing (7). Moreover, subpar vascular responses of the injured tissue, and observed increased
ACL fibroblast difficulty in initiating cell migration and triggering angiogenesis may also play a
role (7,25,26). Additionally, recent studies have also suggested that in anterior cruciate ligament
healing, there is a lack of formation of a bridging matrix that connects the torn ends of the ACL
as seen in other ligaments, such as the MCL (11). Unlike other self-healing ligaments, the ACL
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does not form this temporary "bloody clot" or "fibrin scaffolding", likely due to increased
plasmin and urokinase plasminogen activator activity (11,27), and as a result healing cannot be
effectively initiated, regenerative cells cannot be recruited to the site and the
proliferative/reparative phase cannot proceed adequately (11,27,28).
Figure 1.3. Murray 2009 theory on impaired ACL healing. Image previously published in reference (11).
© Elsevier. Reprinted with permission.
1.3. Current Treatments
After ACL rupture, knee instability occurs, especially in young and active patients.
Currently, surgical reconstruction is the gold standard for ACL repair, especially for patients that
wish to continue with athletic and active lifestyles (9,23,29-31). To date, there are only a few
materials available for the repair of ACL injuries requiring surgical intervention. Biological
grafts available include autografts and allografts. Autografts are taken from the own patient to
replace tissue at another site. For ACL reconstruction, these autografts are typically harvested
from the patellar tendon, hamstring tendon, or quadriceps tendon, with an overall reconstruction
success rate upwards of 70% (9,29-31) (Figure 1.2). Though the choice of autograft is largely
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dependent on surgeon preference, patellar and hamstrings tendons are the most commonly used
grafts, with failure rates of 7 and 16%, respectively (9,29). In addition to the risk of graft failure,
this technique is limited by the amount of tissue that can be obtained from the donor site, and has
the potential to cause donor site morbidity, including functional muscle weakness, chronic
articular pain, patellar rupture, and increased long-term risk of osteoarthritis (17,29,31-34).
However, it is important to note that, even though some types of grafts may accelerate the
development of osteoarthritis, evidence suggests that the risk of developing osteoarthritis post-
ACL injury is high regardless of the type of treatment (35,36); and that surgical intervention does
not decrease the long-term incidence of osteoarthritis compared to conservatively-treated injuries
(35).
In addition to autografts, allografts from cadavers may also be used as repair tissues.
Allografts have the advantage of not requiring donor sites, reducing surgery duration and
providing a more ample source of tissue (9,17,29,31). However, they have the potential to carry
infection, cause an immunogenic response in the recipient, and are difficult to sterilize without
damaging the biomechanical properties of the graft (9,17,29). Furthenrmore, the failure rate of
allografts can be as high as three times that of autografts, especially in younger populations
(9,31,37).
Alternatively, there are a few synthetic materials that have been unsuccessfully
investigated for ACL repair, such as the Gore-Tex and Leeds-Keio prostheses (23). Although
approved for limited use by the FDA, these materials invariably fail over time by mechanical
wear and tear, leading to mechanical failure and loosening of the grafts, synovitis, and knee
instability (17,23).
20
Patella
Bone-tendon
graft
CHealthwise, Incorporated
Figure 1.4. Patellar autograft diagram. Image courtesy of CHealthwise, Inc., with permission.
1.4. Novel Approaches
Given the shortcomings of currently available options for ACL reconstruction and repair,
the development of techniques that promote the healing of ligaments and tendons is of increased
importance in Orthopaedics. Tissue Engineering and Regenerative Medicine have recently
provided new pathways for potential tissue repair, where cell sources, biological regulators and
biomaterial scaffolds can serve as instruments to improve tissue regeneration. Steadman and
colleagues have developed the Healing Response Technique (HRT) to enhance primary ACL
repair by an approach similar to cartilage microfracture surgery (10,38,39). The technique
involves the microdrilling of holes at the proximal end of the injured ligament and through the
ligament's origin, which should allow mesenchymal stem cells, biological regulators and clotting
factors to reach the site of injury (10,38). A primary repair approach, where the torn ends are
approximated and surgically repaired with a suture, is then performed on the ligament (10,38).
Follow-up studies have been contradicting in demonstrating the success of the technique, with a
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1.
study by Steadman and colleagues reporting that HRT is effective in returning patients to normal
levels of recreational activity with less than 9% of patients needing subsequent ACL
reconstruction, while Wasmaier and group report reconstruction rates as high as 36% and did not
see better outcomes when compared to conservative treatment options (40,41). Even though the
technique shows promise, modifications and improvements are needed to ensure positive long-
term outcomes.
Murray and colleagues have also developed a promising technique known as
bioenhanced ACL repair (11). This approach utilizes a combination of collagen hydrogels or
sponges and platelet-rich plasma (PRP) to create collagen-platelet constructs used to augment
and enhance a primary ACL repair (11,42-47). The PRP serves as a source of biological factors
and clotting factors required for wound healing, while the collagen sponges serve as a platelet
activator and a vehicle to deliver and retain PRP at the injury site (45,46). The technique has
shown positive results in artificially created ACL transections by improving the biomechanical
functioning of primary ACL repairs, especially when supplemented with bone-to-bone suture
fixation, which essentially acts as an additional scaffold providing structural support to the
construct and stabilizing the knee (42,44,47,48). A drawback of this technique is the use of an
artificial injury model, where the ligament transection is created cleanly and the ACL remnants
are essentially intact, easily approximated and repaired immediately post-transection (42).
Moreover, several groups have established that surgical transections are not clinically
comparable to real ligament injuries (49-51). The technique has shown negative results when
bioenhanced primary repair is delayed even for two weeks (52). It would be interesting to see the
effectiveness of the technique in ACL injury models more similar to observed clinical scenarios,
where the ACL stumps are severely damaged, retracted, inflamed, and reconstructive surgery
generally delayed for two to four weeks (12,53-56).
Laurencin and group have developed yet another ACL engineering technique with
promising potential (17,57). Three-dimensional, braided poly-L-lactide (PLLA) scaffolds seeded
with primary ACL cells are used as biodegradable, synthetic allografts for ACL reconstruction
(17,57-62). The grafts have shown appropriate tissue ingrowth, collagen and cellular penetration,
vascularization, and short-term biomechanical stability (57). However, when tested in vivo in
rabbits, the constructs failed biomechanically after 12 weeks (57). Goh and others have used a
similar approach with silk or collagen scaffolds seeded with MSCs, achieving improved longer-
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term biomechanical stability but still far from levels observed in native ACL (4,63-65). The
method has encouraging features for ACL reconstruction, and with appropriate adaptations and
combination with additional regenerative therapies may help advance the field of ligament repair.
1.5. Our Approach
As the complex biomechanical and sensory role of the ACL is better understood,
increased interest has been placed in the primary repair of ACL injuries supplemented with
localized regenerative medicine therapies (10,11,31,48). Sparing of the existing vascular supply,
as well as the intricate array of neurosensory machinery, may help increase the long-term success
of ACL repair and lead to better outcomes (10,28,66). The goal of this thesis is to establish the
framework of a technique to create functional ACL tissue from autologous mesenchymal stem
cells cultured in conjunction with primary ACL fibroblasts in a stable hydrogel matrix seeded on
a resorbable polymer scaffold. The hydrogel serves as the cell delivery vehicle, ensuring
homogeneous cell seeding of the polymer scaffold. The scaffold serves as the load-bearing
material during the time of ligament regeneration. Our vision is to introduce a multi-component,
combinatorial regenerative construct that may overcome the difficulties encountered by the ACL
regenerative approaches introduced above. Two aspects of the thesis advocate the approach may
have better outcomes. First, recent studies have shown that indirect and/or direct co-culture of
MSCs and fibroblasts results in increased expression of tissue-specific markers, cell proliferation,
DNA content and collagen production, and triggers differentiation of MSCs towards fibroblastic
lineages (64,67-69). Second, current reports have shown that MSCs may not only provide cells
for repair, but may also act as accessory cells that trigger regenerative responses in cells native to
other tissues (70-72). Furthennore, MSCs have shown anti-inflammatory and
immunomodulatory properties in vivo (73-75). Thus, combining MSCs and ACL fibroblasts may
provide a double source of cells and regulators from which ACL can be regenerated (Figure 1.3).
The thesis explores the effects of co-culture in ACL constructs and the behavior of the cells in
two- and three-dimensional in vitro culture.
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1.6. Research Aims
1. Characterization of tibial mesenchymal stem cells. Hypothesize that proximal tibial
MSCs have the same differentiation potential as other bone marrow-derived MSCs.
2. Characterization of the co-culture effects of primary ACL fibroblasts and MSCs in vitro.
Hypothesize that co-culturing MSCs with ACL cells leads to an enhanced regenerative
response compared to either population alone.
3. In vitro development of a construct for primary ACL augmentation repair with a
biodegradable scaffold based on poly(glycolic) acid: trimethylene carbonate (PGA:TMC)
combined with a hydrogel seeded with autologous MSCs and primary ACL fibroblasts
under dynamic tensile loading. Hypothesize that combining MSCs with primary ACL
cells in a hydrogel loaded in a biodegradable scaffold enhances the regenerative response,
particularly in tensile loading environments.
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Chapter 2.
Feasibility of Tibial Bone Marrow-Derived Mesenchymal Stem
Cells for Orthopaedic Tissue Engineering
2.1. Overview of Mesenchymal Stem Cells
S ince their initial discovery by Friedstein and colleagues (76,77), mesenchymal stem cells(MSCs) have kindled vigorous interest from scientists in various fields, especially Tissue
Engineering and Regenerative Medicine. The existence of an adult stem cell with the ability to
differentiate into a wide variety of tissues not only bypassed ethical dilemmas faced by stem
cell researchers dealing with embryonic stem cells, but also provided a potential source of
autologous cells that could be seamlessly harvested and tolerated by patients in need of cell
therapies, organ regeneration and/or transplantation (72,78).
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Figure 2.1. Mesenchymal stem cell differentiation. This image, "The Mesengenic Process", was
published in references (72,79) V Elsevier. Reprinted with permission.
Although MSCs were first isolated from bone marrow (76), they have since been
identified in practically every tissue in the body (70-73,80-86). Controversy about the true name,
identity, meaning of the term, and behavior of MSCs is ongoing (reviewed in (87)).
Nevertheless, the scientific consensus is that MSCs, with mesenchymal stem cell being the
preferred denotation, are non-hematopoietic, multipotent, self-renewing stem cells made up of a
mixed cell population with typical fibroblastic morphology capable of differentiating into a
wide array of tissues, including bone, fat, cartilage, muscle, ligament, tendon and others
(72,77,79,82,83,85,86,88) (Figure 2.1). Moreover, the literature has also described their ability
to differentiate into tissues of neuroectodermal/ectodermal, and endodermal origins (84,85).
Even though complete knowledge of the biologic role of MSCs is still lacking,
significant advances have been made in the understanding of MSC physiology (70,73,84,88).
Initially thought of only as a stem cell source for the maintenance of tissues and/or the
regeneration of damaged tissues in vivo (88), MSCs have more recently been observed to also
act as secretory cells that release biological factors that can stimulate the recruitment and
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proliferation of native tissue cells, enhance angiogenesis, while also inhibiting apoptosis and
fibrosis (70-72,86,89). In addition, MSCs have also been observed to play a role in the
regulation of immunologic and inflammatory responses (70,73-75,82,90). Some reports suggest
MSCs have immunosuppressive characteristics, regulating dendritic cell, T-cell and B-cell
functions (70,73,74,82); while others suggest MSCs secrete anti- and pro-inflammatory
cytokines (70,90). Thus, MSCs may assist tissue regeneration in more ways than previously
believed by providing raw stem cells for tissue replenishment, while also secreting local and
systemic factors that can promote and enhance tissue repair (70-72,88).
2.2. Mesenchymal Stem Cell Sources, Isolation and Identification
As extensively reported by da Silva Meirelles and others, MSCs have been isolated from
essentially everywhere in the body (70-72,83-86). However, the specific properties of MSC
populations derived from different tissues vary depending on tissue origins (85). While the
profile of surface markers observed is similar across MSCs from various tissue origins, their
differentiation potentials and extent of differentiation are often very different (85). Further,
others suggest their biosecretory activities can also be different and dependent on tissue of
origin (71,91). These observations suggest that the source of MSCs for tissue engineering
applications should be carefully assessed depending on the tissue being regenerated and the
desired outcome (71,85,92).
Our interest in the regeneration of musculoskeletal tissues for Orthopaedic tissue
engineering and eagerness to translate our technique to the clinic for surgical ligament repair
advocates for bone marrow as the preferred source of MSCs. First, bone marrow MSCs
(BMSCs) were the original population described by scientists, and is perhaps the best
characterized and whose behavior is better understood (71,72,78). Second, BMSCs by default
tend to go down their mesenchymal lineage, more easily differentiating into skeletal connective
tissue cells than MSCs from other sources (71,84,87,88,93). In fact, Bianco and others (93,94)
recognize bone marrow MSCs as "skeletal stem cells", underscoring their increased ease and
potential in generating skeletal cells, including osteoblasts, chondrocytes, adipocytes and
fibroblasts, with in vivo "natural" assays and without the need for artificial interventions
(93,95,96). Though the use of alternatives sources for MSC harvest such as fat (97), peripheral
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blood (97,98) or dental pulp (93) may increase convenience, experimental evidence suggests
bone marrow-derived MSCs have the greater ability to differentiate into skeletal tissues
(71,93,95,96). In fact, studies in marrow, adipose and peripheral blood imply bone marrow-
derived MSCs have the greater potential for orthopaedic tissue engineering, and particularly
ligament regeneration (92,99,100). For example, in a study with adipose-derived MSCs
(ADMSCs) cultured in vitro with growth factors, the cells did not show a significant or stable
increase in the expression of ligament-associated markers (92). Peripheral blood is also a
theoretically attractive source of MSCs (97,98,101). However, some groups have questioned the
true origin of peripheral blood-derived MSCs (PBMSCs), suggesting they are biologically
different from BMSCs and very scarce (102), released or mobilized from other tissues into the
circulation after injury or other in vivo physiological or pathological processes (85,103-105), or
observed only when derived from cancer patients undergoing chemotherapy (94,106); while
others have only had success in isolating PBMSCs when dealing with fetal or umbilical cord
blood (88,107-109). Even more so, many groups have been unable to isolate MSCs from
peripheral blood (85,105,110,111). These observations pooled together insinuate a lack of true
understanding of the biology, origin and behavior of alternative MSC sources, reason enough to
lead our group to focus on the well-characterized bone marrow MSCs.
Bone marrow is a form of reticular connective tissue composed of extracellular matrix,
hematopoietic cells and stem cells, white blood cells, adipocytes, and MSCs among others (83).
Bone marrow is located within bones, particularly in the pelvis and long bones. In order to
obtain pure MSC cultures, the cells must be separated from the rest of the components of bone
marrow. Typically, explant cultures are established by diluting bone marrow aspirates in
nutritional cell media and allowed to grow in tissue culture flasks or dishes (83). MSC cultures
result as the cells attach to the flasks and the rest of the marrow components are washed away
with media changes (83). If increased purity or faster isolation is desired, density gradient
centrifugation methods, where components are separated into layers based on their densities,
have been used (112-115). Finally, commercially available syringe filters specific for bone
marrow-derived MSCs have recently been used for diluted bone marrow aspirates (116). The
device utilizes a bi-directional non-woven filter in a column to selectively trap nucleated cells
during forward flow while allowing other marrow components to pass through, the nucleated
cells are then harvested via reverse flow (116). The method has the potential to significantly
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lower isolation times during surgical procedures, especially when compared to explant or
density gradient centrifugation methods (116).
To date, no single marker has been discovered to uniquely identify MSCs. Because of
this the International Society for Cellular Therapy (ISCT) published a guideline to establish the
minimal criteria to define the identity of MSCs (117): (1) cells must adhere to tissue culture
plastic; (2) cells must express surface markers CD105, CD73 and CD90, while not expressing
CD45, CD34, CD14 or CD1 lb, CD79a or CD19 and HLA-DR; and (3) cells must differentiate
to osteogenic, adipogenic and chondrogenic lineages in in vitro assays (117). It is important to
note that this is a minimal criteria list, since MSCs are known to be positive and negative for a
variety of additional non-specific surface markers, and are able to differentiate into a variety of
additional tissues (73,83,84).
2.3. Tibial Bone Marrow-Derived Mesenchymal Stem Cells
Using MSCs for ligament tissue engineering necessitates the procurement of bone
marrow from sites that would seamlessly integrate with a site-specific surgical procedure, avoid
increasing patient discomfort and pain, and provide a sufficient amount of cells for efficient
regeneration (114). Currently, the pelvis is the preferred site for bone marrow harvest, with the
posterior superior iliac spine being the most common site ((118), reviewed in (119)). However,
for upper and lower extremity procedures, interventions in the pelvis would require patient
repositioning and a second surgical site (114). Thus, alternative sources of BMSCs have been of
increased interest in regenerative Orthopaedics. Recent studies have explored the use of
proximal humerus and distal femur bone marrow as a source of MSC-like cells for skeletal
tissue regeneration (113,114,120). The studies are well performed, but fall short of fully
characterizing the cell isolates as true MSCs, and fail to compare their technique to additional
MSC isolation methods that could more easily integrate to a surgery (116).
Another source that is directly in the operative field during knee surgeries is the
proximal tibia. Many orthopaedic procedures of the knee require tibial interventions, including
autologous chondrocyte implantations (ACI) with tibial tubercle osteotomies (TTO) (121-123),
and ACL reconstructions, where femoral and tibial tunnels are routinely created (30). Thus, the
tibia is a source that has been unexplored and may offer an additional site to the distal femur for
30
MSC isolation. In collaboration with Dr. Andreas Gomoll from the Cartilage Repair Center in
the Department of Orthopaedic Surgery at the Brigham and Women's Hospital, our laboratory
pursued a clinical study with human tibial bone marrow. Our goal was to develop a simple and
integrated protocol for tibial bone marrow harvest during ACL reconstructions and/or ACIs
with TTOs, and to isolate and fully characterize the MSCs obtained from the aspirates for tissue
engineering applications in Orthopaedics.
2.3.1. Preliminary Evaluation of Isolation Methodologies
In a preliminary study, we compared three methods of MSC isolation using sheep bone
marrow: explant culture, density gradient centrifugation, and a more recently introduced
protocol utilizing a bone marrow MSC syringe filter device (116). Iliac crest bone marrow
aspirates post-euthanasia were obtained from 6 to 8 month old sheep via the tissue-sharing
program of Institutional Animal Care and Use Committee (IACUC)-approved protocols at
Harvard Medical School and the Brigham and Women's Hospital. The isolated cells were
assessed for their differentiation potential.
2.3.1.1. Materials and Methods
Tissue harvest and cell isolation
Explant method
As previously described (99,124), 5-10 ml of BM from the iliac crest were aspirated
with a 16-gauge needle attached to a syringe with 0.5 ml sodium heparin (APP
Pharmaceuticals) and seeded in T-75 flasks (BD Falcon) at a 1 ml BM to 9 ml media ratio with
DMEM (Gibco) with 10% FBS (Gibco) and 1% antibiotic mixture (BM DMEM). Bone
marrow-derived mesenchymal stem cells were isolated by their ability to attach to tissue culture
plastic (99,124).
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Density gradient method
The density gradient Ficoll-Paque PREMIUM 1.073 (GE Healthcare), designed for
optimal isolation of mononuclear cells (including MSCs) from blood and bone marrow, was
used. MSCs were isolated following the manufacturer's protocol. Briefly, 2 ml of BM were
diluted with 2 ml of sterile HBSS-- (Invitrogen). The final 4 ml volume of diluted marrow was
carefully layered on top of 3 ml of Ficoll-Paque PREMIUM 1.073 in a sterile 15 ml conical tube
(BD Falcon) and centrifuged at 400 x g for 35 minutes at 20'C. Carefully, the layer of
mononuclear cells (-2 ml) was transferred to a new sterile 15 ml conical tube, resuspended with
-6 ml of HBSS--, and centrifuged at 500 x g for 15 minutes at 20'C. The pellet was washed
once more by resuspending in ~6 ml HBSS--, and centrifuging at 500 x g for 10 minutes at
20'C. The cell pellet was then seeded in T-75 flasks with BM DMEM.
Filter device method
A bone marrow MSC Separation Device - Basic Set (Kaneka, Japan) was used as
previously described (116), and following manufacturer's protocols. Briefly, 5-15 ml of BM
were diluted in two equal volumes of HBSS--. The filter device was primed with 50 ml of
HBSS- - to flush the air out of the column. The diluted bone marrow was then attached to the
forward flow side of the filter and allowed to stand vertically for 3 minutes to separate the
marrow fat from the dilution. The bone marrow fluid was the forward flushed through the filter
at 6 mI/min into a biohazard disposal container. The filter was then washed with 30 ml of
HBSS- - in forward flow direction at a rate of 6 ml/min. The filter was then reversed and 30 ml
of BM DMEM were flushed in reverse flow at a rate of about 10 ml/sec into a sterile 50 ml
conical tube. The harvested fluid was centrifuged at 260 x g for 6 min, and the cell pellet
resuspended in BM DMEM and seeded in T-75 flasks.
All cells were grown to passages 2 or 3. Viability was determined by the trypan-blue
(Sigma) exclusion method. MSCs were not allowed to reach more than 60-70% confluency
before passaging. Culture medium was changed twice a week.
Osteogenesis
MSCs were seeded in 24-well plates (BD Falcon) at a density of 4.2 x 103 cells/cm 2 and
cultured in BM DMEM until 50-70% confluency was reached. Medium was then replaced with
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osteogenic differentiation media composed of a-MEM Basal Medium (Gibco) supplemented
with dexamethasone, ascorbate, and b-glycerophosphate (Osteogenic Supplement, R&D
Systems). Media was changed every 3 days for 2 weeks. Cultures were then washed carefully
with HBSS--, fixed with 10% formalin (Sigma) for 45 minutes and rinsed with distilled water.
Alizarin Red S staining solution was freshly made with 2g Alizarin Red S (EMD Chemicals) in
100 ml distilled water, adjusting pH to 4.1-4.3 with 0.1% NH40H. Cell monolayers were then
covered with staining solution and incubated at room temperature in the dark for 45 minutes.
Wells were then rinsed with distilled water and imaged using an Olympus IX70 microscope
equipped with a SPOT digital camera and image processing software (Diagnostic Instruments).
Adipogenesis
MSCs were seeded in 24-well plates (BD Falcon) at a density of 2 x 104 cells/cm 2 and
cultured in BM DMEM until 100% confluency was reached. Medium was then replaced with
adipogenic differentiation media composed of a-MEM Basal Medium (Gibco) supplemented
with hydrocortisone, isobutylmethylxanthine and indomethacin in 95% ethanol (Adipogenic
Supplement, R&D Systems). Media was changed every 3 days for 2 weeks. Cultures were then
washed carefully with HBSS--, fixed with 10% formalin (Sigma) for 45 minutes and rinsed with
distilled water. Wells were then covered with 60% isopropanol for 5 minutes and then stained
with 0.3% Oil Red 0 staining solution for 15 minutes at room temperature. Wells were then
rinsed with distilled water and imaged using an Olympus IX70 microscope equipped with a
SPOT digital camera and image processing software (Diagnostic Instruments).
Chondrogenesis
Approximately 250,000 MSCs were transferred to a 15 mL conical tube and centrifuged
at 200 x g for 5 minutes at room temperature. Medium was discarded, cells then resuspended in
0.5 mL of chondrogenic differentiation medium and centrifuged at 200 x g for 5 minutes
without discarding medium. Chondrogenic differentiation medium was composed of DMEM/F-
12 basal medium (Gibco) supplemented with 1% ITS supplement (R&D Systems) and
dexamethasone, ascorbate-phosphate, proline, pyruvate and TFG-b3 (Chondrogenic Supplement,
R&D Systems). Pellets were then incubated at 37'C and 5% CO2 for 2 weeks. Media was
changed every 3 days for 2 weeks. Pellets were then washed carefully with PBS, fixed with
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10% formalin (Sigma) for 45 minutes, and 5-7um frozen sections were obtained for staining.
Slides were stained with Hematoxylin I solution (Richard-Allan Scientific) for 10 minutes,
rinsed in tap water for 5 minutes, then incubated in 0.001% Fast Green (Fisher) solution for 5
minutes. 1 % Acetic Acid (Fisher) was then added for 15 seconds, followed by 0.1% Safranin 0
solution (Fisher) for 5 minutes. Slides were rinsed and mounted for imaging using an Olympus
IX70 microscope equipped with a SPOT digital camera and image processing software
(Diagnostic Instruments).
2.3.1.2. Results and Conclusions
Our goal for this preliminary evaluation of isolation methods was to ensure consistent
results in MSC harvesting, particularly focusing on our success with the filter device. Our
results showed that after 2 weeks of in vitro differentiation, all three methods successfully
generated bone, fat and cartilage tissues (Figure 2.2). Alizarin Red S is a special stain that is
used to establish the presence of calcium deposits within osteogenic cells; bright red coloration
signals a positive stain (Fig. 2.2 A, B, C). Oil Red 0 is a fat-soluble dye used as a special stain
for the identification of lipids within adipocytes; bright red vacuoles signal a positive stain (Fig.
2.2 D, E, F). Safranin-O is a special stain used to identify proteoglycans and sulfated
glycosaminoglycans, major components of the cartilage ECM; a pink to dark red color signals a
positive stain (Fig. 2.2 G, H, I).
The positive results of our preliminary study suggested to our team that for future MSC
harvesting in the clinical setting, either the density gradient method or the filter device method
would offer the most promise, as they require significantly less amount of time before a purified
collection of MSCs can be obtained when compared to the explant technique.
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Figure 2.2. Sheep MSC differentiation assays. Each MSC isolation method (explant, density gradient
and filter device) was assayed for cell differentiability to osteogenic, adipogenic and chondrogenic
lineages. Panels (A-C) show osteogenic stains performed with Alizarin Red S (scale bar = 100 [tm), red
is a positive stain. Panels (D-F) show adipogenic stains performed with Oil Red 0 (scale bar = 50 [tm),
intracellular fat droplets in red signal a positive stain. Panels (G-I) show chondrogenic stains performed
with Safranin 0 (scale bar = 50 [rm), pink to dark red coloring signals a positive stain for cartilage
proteoglycans and glycosaminoglycans.
2.3.2. Characterization of Human Tibial Bone Marrow-Derived
Mesenchymal Stem Cells
Our ultimate clinical interest is to isolate MSCs from the proximal tibia for the
regeneration of ligament, cartilage and other musculoskeletal tissues. To assess the properties of
MSCs isolated from tibial bone marrow, an Institutional Review Board-approved clinical study
was initiated with the collaboration of the Department of Orthopaedic Surgery at the Brigham
and Women's Hospital. The objective of the study was to characterize the properties of MSCs
obtained from the bone marrow of the proximal tibia to devise a single-stage procedure that
could offer advantages to patients, including decreased morbidity and reduced costs.
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Patients scheduled to undergo procedures that affect the proximal tibia were eligible for
participation. These procedures included anterior cruciate ligament reconstruction (ACL), tibial
tubercle osteotomy (TTO) and high-tibial osteotomy. These specific procedures were selected
because during the normal course of the procedure the cortical bone of the proximal tibia has to
be opened, thus providing easy access to the bone marrow, without causing additional trauma
above and beyond that of the index surgical intervention. Sixteen patients aged 18 to 55 were
enrolled and informed consented, since this patient cohort is the target population for eventual
ligament and cartilage repair with the mesenchymal stem cell-based approaches being
investigated in this thesis.
The tibial aspirates were processed via the density gradient centrifugation or with the
filter device for MSC isolation, and the cells were characterized in vitro according to the
minimal criteria set forth by the ISCT (117).
2.3.2.1. Materials and Methods
Cell isolation, the MSC differentiation assays, and the osteogenic and adipogenic
staining assays were performed as described in the sheep preliminary study detailed in section
2.3.1.1.
Tissue harvest
Tibial bone marrow was harvested during ACL reconstructions or TTO procedures.
After drilling on the tibia, a 14-gauge Angiocath Autoguard Shielded catheter (Becton
Dickinson) was inserted into the drilled orifice. The guiding needle was removed, and a 10 ml
syringe pre-coated with 5000 units of sodium heparin solution was adapted to the catheter. An
assistant applied pressure to the surroundings of the catheter at the insertion site to prevent air
leaks and 2 to 10 ml of bone marrow were suctioned into the syringe. The marrow was
transferred to sodium heparin BD Vacutainer tubes, transported to the laboratory within 30-60
minutes of harvest and cell isolation perfonrmed. The harvests added less than 5 minutes to the
entire surgical procedure.
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Cartilage immunofluorescence staining
Cartilage pellets were washed carefully with PBS, fixed with 4% paraformaldehyde
(Wako) for 20 minutes at room temperature, then washed twice with PBS for 5 minutes. Pellets
were then placed in a cryomold (Sakura), embedded in OCT compound (Sakura), and rapidly
frozen in a mix of dry ice and 100% ethanol. Serial 5-7 gm thick cross-sections were cut and
mounted on Superfrost/Plus slides (Fisher). Slides were washed three times with PBS, then
permeabilized and blocked with 0.3% TritonX-100 (Sigma), 1% BSA (Fisher), and 10% normal
donkey serum (Jackson ImmunoResearch) for 45 min at room temperature. Slides were then
incubated in goat anti-human aggrecan antibody (1:100, R&D Systems #962644) overnight at
4'C. Slides were then washed three times with PBS supplemented with 1% BSA for 5 minutes,
then incubated for 1 hr with either donkey anti-goat FITC secondary antibody (1:200,
JacksonImmunoResearch) or donkey anti-goat Alexa Fluor 555 (1:200, Invitrogen) at room
temperature. DAPI (1:500, Sigma) counterstain was added for 10 minutes at room temperature.
Slides were washed twice with PBS for 5 minutes, then mounted with Vectashield (Vector) and
imaged with an Olympus IX70 fluorescent microscope and a SPOT digital camera and image
processing software (Diagnostic Instruments).
Flow cytometry for surface marker identification
A BD Stemflow Human MSC Analysis Kit (BD Biosciences) was used with
manufacturer's protocol. Briefly, human MSCs were detached from tissue culture flasks using
Accutase Cell Detachment Solution (BD Biosciences) for 10 minutes at 37 0 C with gentle
shaking, washed twice with sterile HBSS- - + 2% FBS, and resuspended in HBSS- - + 2% FBS
at a concentration of 5 x 106 cells/ml. For each sample, seven 5 ml polystyrene FACS-ready
tubes with cell-strainer cap were prepared with the following contents: tube (1) 5 d Mouse
Anti-Human CD90; (2) 5 tl PE Mouse Anti-Human CD44; (3) 5 K PerCP-Cy 5.5 Mouse Anti-
Human CD105; (4) 5 tl APC Mouse Anti-Human CD73; (5) Empty control; (6) 20 tl human
MSC positive isotype control cocktail (nIgGI for KFITC, KPerCP-Cy5.5 and KAPC), and 20 [d
PE human MSC negative isotype control cocktail (mlgG 1 for KPE and mIgG2a for KPE); (7) 20
K human MSC positive cocktail (CD90 FITC, CD105 PerCP-Cy5.5, CD73 APC), and 20 K PE
human MSC negative cocktail (CD34 PE, CD lb PE, CD19 PE, CD45 PE and HLA-DR PE).
100 1t of the cell suspension was added to each tube and incubated in the dark for 30 minutes
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on ice. The cells were then washed twice with HBSS- - + 2% FBS, and resuspended in 300 d of
HBSS-- + 2% FBS for analysis. An LSR Fortessa Cell Analyzer (BD Biosciences) was used.
2.3.2.2. Results
The human differentiation assays confirmed our belief that the differentiation potential
of tibial bone marrow-derived MSCs is similar to that of hip-derived bone marrow MSCs
(Figure 2.3). Both isolation methods, the density gradient and the filter device, produced plastic-
adherent cells that when cultured in specific differentiation media yielded positive osteogenic
(Fig. 2.3A and B, Alizarin Red S), adipogenic (Fig. 2.3C and D, Oil Red 0), and chondrogenic
(Fig. 2.3E and F, immunofluorescence with goat anti-human Aggrecan antibody) stains.
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Figure 2.3. Human MSC differentiation assays. Density gradient and filter device isolations were
assayed for cell differentiability to osteogenic, adipogenic and chondrogenic lineages. Panels (A) and (B)
show osteogenic stains performed with Alizarin Red S (scale bar = 100 [tm), red is a positive stain.
Panels (C) and (D) show adipogenic stains performed with Oil Red 0 (scale bar = 100 [rm), intracellular
fat droplets in red signal a positive stain. Panels (E) and (F) show chondrogenic stains performed via
immunofluorescence with goat anti-human aggrecan primary antibody, and FITC (green) or Alexa Fluor
555 (orange) secondary antibodies; DAPI nuclear stain is blue (scale bar = 100 [tm).
In addition, flow cytometric analysis confirmed the presence and absence of the
specified surface markers for human MSC identification as set forth by the ISCT guidelines
(117) (Figure 2.4).
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Figure 2.4. Flow cytometric analysis of tibial bone marrow-derived Human MSCs isolated via density
gradient and filter device. Data confirm the presence of MSCs from both isolation techniques by surface
marker analysis per the recommendations of the ISCT guidelines (117). Panels (A) and (D) show lineage
negative cells for surface markers CD34, CD45, CD14, CD19 and HLA-DR for each isolation method.
Panel (B) shows CD90+ and CD105+ cells from density gradient isolations. Panel (C) shows CD73+
cells from density gradient isolations. Panel (E) shows CD90+ and CD73+ cells, while panel (F) shows
CD105+ cells, both from filter device isolations. Surface marker and fluorochrome pairings were as
follows: PE (phycoerythrin) paired to CD34, CD45, CD 14, CD19 and HLA-DR; APC (allophycocyanin)
paired to CD73; FITC (fluorescein isothiocyanate) paired to CD90; PerCP-Cy 5.5 (Peridinin-chlorophyll
proteins-cyanine 5.5) paired to CD 105.
2.4. Conclusions and Next Steps
The identification of a MSC harvesting sites located close to the surgical site of common
orthopaedic knee procedures is important in regenerative Orthopaedics, as it would improve
surgical outcomes and reduce risks (113,114). As expected, our human tibial bone marrow
study confirmed that MSCs are present in and have very similar properties to MSCs isolated
from hip, humerus and femur marrow (113,114,124). More specifically, in contrast to other
studies, our results characterized tibial marrow-derived MSCs in greater detail and followed the
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guidelines established by the ISCT (113,114,117,124). Our observations suggest that marrow
aspirates obtained from the tibia can be used to procure MSCs used in future tissue engineering
techniques within regenerative Orthopaedics.
Our IRB-approved study is still active and currently enrolling patients to [1] optimize
the intraoperative harvesting procedure for various types of surgeries, including TTOs and ACL
reconstructions; [2] to determine the volume of harvested bone marrow that yields an optimal
number of colony forming units of MSCs; and [3] to optimize the bone marrow processing
timing for optimal isolation of viable MSCs. Furthermore, our team is considering expanding
the study to include the characterization of distal femur bone marrow MSCs following the ISCT
minimal criteria (117).
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Chapter 3.
Effect on Ligament Marker Expression by Direct-Contact Co-
Culture of Mesenchymal Stem Cells and Anterior Cruciate
Ligament Cells (99 )t
3.1. Abstract
L igament and tendon repair is an important topic in orthopedic tissue engineering; however,
the cell source for tissue regeneration has been a controversial issue. Until now, scientists
have been split between the use of primary ligament fibroblasts or marrow-derived mesenchymal
stem cells. The objective of this study was to show that a co-culture of anterior cruciate ligament
(ACL) cells and mesenchymal stem cells (MSCs) has a beneficial effect on ligament
regeneration that is not observed when utilizing either cell source independently. Autologous
ACL cells (ACLc) and MSCs were isolated from Yorkshire pigs, expanded in vitro and cultured
in multiwell plates in varying %ACL/%MSCs ratios (100/0, 75/25, 50/50, 25/75 and 0/100) for
two and four weeks. Quantitative mRNA expression analysis and immunofluorescent staining for
ligament markers Collagen-I, Collagen-III and Tenascin-C were performed. We show that
Collagen-I and Tenascin-C expression is significantly enhanced over time in 50/50 co-cultures of
ACLc and MSCs (p<0.03), but not in other groups. In addition, Collagen-III expression was
Chapter first published as an original article in Tissue Engineering Part A 18(23-24), 2549-2558, 2012, C Mary Ann Liebert,
Inc., publishers. Included with permission.
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significantly greater in MSC-only cultures (p<0.03), but the Collagen-I to Collagen-III ratio in
50% co-culture was closest to native ligament levels. Finally, Tenascin-C expression at four
weeks was significantly higher (p<0.02) in ACLc and 50% co-culture groups compared to all
others. Immunofluorescent staining results support our mRNA expression data. Overall, 50/50
co-cultures had the highest Collagen-I and Tenascin-C expression, and highest Collagen-I to
Collagen-III ratio. Thus, we conclude that using a 50% co-culture of ACL cells and MSCs,
instead of either cell population alone, may better maintain or even enhance ligament marker
expression and improve healing.
3.2. Introduction
Injuries to the anterior cruciate ligament (ACL) represent one of the most common
sports-related injuries and the most common ligament injury in the knee (17,18). In the United
States there are at least 100,000 ACL repairs performed each year (19). For these reasons, the
development of techniques that promote the healing and repair of ligaments and tendons is of
increased importance in orthopedics.
Tissue engineering principles have recently been applied to the development of novel
ligament regeneration techniques; the ideal cell source, however, has been a controversial topic
within orthopedic tissue engineering. Initial studies, focused on defining the optimal individual
cell source for ligament regeneration, are divided between the use of primary ACL cells (ACLc)
and mesenchymal stem cells (MSCs) (18,21,125). However, new evidence suggests there are
advantages to the use of a co-culture system. Recent reports have established that indirect co-
culture of MSCs and ligament/tendon cells results in an increased expression of ligament/tendon
markers Collagen type I (Collagen-I), Collagen type III (Collagen-Ill) and Tenascin-C in the
MSCs (64,67,68). It was also observed that cell proliferation, DNA content and collagen
production were all increased in MSCs as compared to non-co-cultured controls; the induction of
differentiation of MSCs towards a ligament lineage was also noted (64,67-69). Direct cell-cell
contact between MSCs and a variety of other differentiated cell populations has proven to be a
key determinant of the fate and effect of MSCs in culture (126,127). It has been observed that
cell-cell contact between MSCs and certain fibroblast populations can induce phenotypic
changes in the fibroblast (126,127). Furthermore, recent studies have shown that MSCs have
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anti-inflammatory and immunomodulatory properties in vivo (73-75). These observations have
led some investigators to suggest that MSCs may aid tissue regeneration in more ways than
previously believed (70-72). By introducing co-culture systems, scientists may be able to
enhance the regeneration of tissues by exposing two or more cell populations to each other's
regulatory molecules naturally and simultaneously, or at a sequence dictated by the cells
themselves. All of these studies lead to the conclusion that MSCs can serve both as a cell source
for tissue regeneration and/or as a source of regulatory cues for the differentiation of other cell
types.
More recent studies have identified the presence of MSC-like cells in several tissues,
including ligament and tendons (70-72,80,81). In the body, MSCs appear to function as support
cells that can differentiate into specific cell types to regenerate injured tissues; and can promote
regeneration by providing regulatory cues to native tissue cells that promote angiogenesis,
stimulate progenitor cells from within the injured tissue, and reduce apoptosis and scar formation
(71).
This study was based on the premise that ACLc and MSC co-cultures can initiate a
regenerative response that could stimulate ACL tissue to enhance its own repair. Scientists in the
field of ligament tissue engineering use the expression of Collagen-I, Collagen-III and Tenascin-
C as a tool to evaluate the degree of ligament regeneration (4,64,67-69,128). Microstructurally,
close to 94% of ACL tissue is composed of fascicles of collagen fibers, with the remaining 6%
comprised of cells and additional extracellular matrix components, including Tenascin-C (2,129).
Moreover, approximately 90% of collagen in ACL is type I, with Collagen-III comprising the
remaining 10% (2-4). Our objective was to determine the effects of direct co-culture of a variety
of ratios of ACLc and marrow-derived MSCs on the overall expression of ligament markers in
vitro as a way to elucidate the optimal cell ratio for future ligament tissue engineering studies.
We hypothesized that a co-culture of ACLc and MSCs would potentially enhance the expression
of ligament markers Collagen-I, Collagen-III and Tenascin-C when compared to ACLc or MSCs
cultured independently.
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3.3. Materials and Methods
Tissue harvest and cell isolation
ACL tissue and bone marrow were harvested from 4-8 month old Yorkshire pig legs
purchased from a local butcher house. First, the ACL was isolated by an improvement on the
protocol first developed by Nagineni and adapted by others (21,130-132). ACL tissue was
aseptically dissected and washed in sterile Hank's Buffered Salt Solution, Calcium and
Magnesium free (HBSS--, Invitrogen) and then placed in a Petri dish (BD Falcon) with fresh
HBSS--. Two No. 21 blade scalpels were used to gently scrape off remaining synovial tissue
from the surface of the ligament. The tissue was transferred to a second dish with fresh HBSS--
and scraping was repeated gently. Subsequently, the tissue was transferred to a new dish with 10
ml of Dulbecco's Modified Eagle's Medium (DMEM, Gibco) with 15% fetal bovine serum (FBS,
Gibco), 1% L-glutamine (Gibco), and 1% antibiotic mixture (Gibco) (ACL DMEM). The tissue
was minced with scissors for approximately 10 minutes until all pieces were <1mm long axis
length, and then digested in a mixture of 2.4 U/ml Dispase-II (Roche) and 10 mg/ml Collagenase
D (Roche) solution for 60 min in a 37 0 C shaker. Next, the resulting cell solution was filtered
through a 100 um strainer (BD Falcon) and centrifuged at 260 g for 6 minutes. The ACLc
obtained were resuspended in ACL DMEM and seeded at a density of 27x 103 cells/cm2 in T-75
tissue culture flasks (BD Falcon).
Secondly, bone marrow was aspirated from the distal femoral end of the same pig leg as
previously described (124). Briefly, 3-4 ml of BM were aspirated with a 16-gauge needle
attached to a syringe with 0.5 ml sodium heparin (APP Pharmaceuticals) and seeded in T-75
flasks at a I ml BM to 9 ml media ratio with DMEM with 10% FBS and 1% antibiotic mixture
(BM DMEM). Bone marrow-derived mesenchymal stem cells were isolated by their ability to
attach to tissue culture plastic (124).
All cells were grown to passages 2 or 3. Viability was determined by the trypan-blue
(Sigma) exclusion method. MSCs were not allowed to reach more than 60-70% confluency
before passaging, while ACLc were allowed to reach 100% confluency. Culture medium was
changed twice a week for all cell types.
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Osteogenesis
MSCs were seeded in 24-well plates (BD Falcon) at a density of 4.2 x 103 cells/cm 2 and
cultured in BM DMEM until 50-70% confluency was reached. Medium was then replaced with
osteogenic differentiation media composed of a-MEM Basal Medium (Gibco) supplemented
with dexamethasone, ascorbate, and b-glycerophosphate (Osteogenic Supplement, R&D
Systems). Media was changed every 3 days for 2 weeks. Cultures were then washed carefully
with HBSS--, fixed with 10% formalin (Sigma) for 45 minutes and rinsed with distilled water.
Alizarin Red S staining solution was freshly made with 2g Alizarin Red S (EMD Chemicals) in
100ml distilled water, adjusting pH to 4.1-4.3 with 0.1% NH40H. Cell monolayers were then
covered with staining solution and incubated at room temperature in the dark for 45 minutes.
Wells were then rinsed with distilled water and imaged using an Olympus IX70 microscope
equipped with a SPOT digital camera and image processing software (Diagnostic Instruments).
Adipogenesis
MSCs were seeded in 24-well plates (BD Falcon) at a density of 2 x 104 cells/cm 2 and
cultured in BM DMEM until 100% confluency was reached. Medium was then replaced with
adipogenic differentiation media composed of a-MEM Basal Medium (Gibco) supplemented
with hydrocortisone, isobutylmethylxanthine and indomethacin in 95% ethanol (Adipogenic
Supplement, R&D Systems). Media was changed every 3 days for 2 weeks. Cultures were then
washed carefully with HBSS--, fixed with 10% formalin (Sigma) for 45 minutes and rinsed with
distilled water. Wells were then covered with 60% isopropanol for 5 minutes and then stained
with 0.3% Oil Red 0 staining solution for 15 minutes at room temperature. Wells were then
rinsed with distilled water and imaged using an Olympus IX70 microscope equipped with a
SPOT digital camera and image processing software (Diagnostic Instruments).
Chondrogenesis
250,000 MSCs were transferred to a 15mL conical tube and centrifuged at 200 x g for 5
minutes at room temperature. Medium was discarded, cells then resuspended in 0.5 mL of
chondrogenic differentiation medium and centrifuged at 200 x g for 5 minutes without discarding
medium. Chondrogenic differentiation medium was composed of DMEM/F-12 basal medium
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(Gibco) supplemented with 1% ITS supplement (R&D Systems) and dexamethasone, ascorbate-
phosphate, proline, pyruvate and TFG-b3 (Chondrogenic Supplement, R&D Systems). Pellets
were then incubated at 37C and 5% CO2 for 2 weeks. Media was changed every 3 days for 2
weeks. Pellets were then washed carefully with PBS, fixed with 10% formalin (Sigma) for 45
minutes, and 7um frozen sections were obtained for staining. Slides were stained with
Hematoxylin I solution (Richard-Allan Scientific) for 10 minutes, rinsed in tap water for 5
minutes, then incubated in 0.001% Fast Green (Fisher) solution for 5 minutes. 1% Acetic Acid
(Fisher) was then added for 15 seconds, followed by 0.1% Safranin 0 solution (Fisher) for 5
minutes. Slides were rinsed and mounted for imaging using an Olympus IX70 microscope
equipped with a SPOT digital camera and image processing software (Diagnostic Instruments).
Co-culture assay
Direct contact co-culture between ACLc and MSCs was performed using tissue culture
treated multiwell plates (BD Falcon). Five groups: 100% ACLc/0% MSCs (n=4), 75%
ACLc/25% MSCs (n=3), 50% ACLc/50% MSCs (n=4), 25% ACLc/75% MSCs (n=3), 0%
ACLc/100% MSCs (n=4), were examined in multiwell plates seeded at 2,500 total cells/cm 2 for
14 and 28 days. A control with 50% ACLc/0% MSCs (total of 1,250 ACLc/cm 2, n=3) was also
examined. ACL DMEM was used for all co-culture experiments and was changed twice per
week.
Quantitative RT-PCR
Expression of ligament markers Collagen-1, Collagen-III and Tenascin-C was quantified
by real-time PCR. Total RNA was isolated from cells freshly harvested from ACL tissue (n=3)
and from each well at 14 and 28 days of co-culture using an RNeasy Plus Midi kit (Qiagen) in
accordance with the manufacturer's protocol. Total RNA (1 Ug per sample) was then reverse-
transcribed in a 20 [tl total reaction volume using a High-Capacity cDNA Reverse Transcription
kit (Applied Biosystems) according to the manufacturer's specifications. The 20 d samples were
loaded onto a Mastercycler (Eppendorf) with the following program: 25'C 10 min - 37'C 120
min - 85'C 5 min. Next, 2 al of a 1:10 dilution of the RT reaction product was subjected to
quantitative PCR (qPCR) using an iQ SYBR Green Supermix kit in 20 d reactions (Biorad). A
C100 Thermal Cycler (Biorad) was used with the following program: 95'C 3 min, 1 cycle; 95 'C
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10 sec -* 64 'C 30 sec, repeat for 40 cycles total; 95 'C 10 sec --+ 65 'C 5 sec, 1 cycle. 18s
rRNA was used as the housekeeping gene for normalization. Preliminary mRNA studies showed
that 18s rRNA levels remained stable over time and across ACLc, MSCs and ACLc/MSCs co-
cultures (data not shown). Custom forward and reverse gene-specific primers for Collagen-I,
Collagen-IIl, Tenascin-C and 18s rRNA are shown in Table 3.1. Pig liver tissue was used as a
negative control. Dissociation and amplification curve analysis was performed with the Biorad
CFX Manager software. Gene expression was obtained using the Pfaffl method to account for
individual reaction efficiencies using freshly harvested native ACLc as the calibrator sample
(133). For freshly harvested native ACLc expression analysis, pig liver was used as the calibrator
sample.
Immunofluorescence
Wells were fixed with 4% paraformaldehyde (Wako) for 20 min at room temperature,
washed with PBS, then permeabilized and blocked with 0.3% TritonX-100 (Sigma), 1% BSA
(Fisher), and 10% normal goat serum (Jackson ImmunoResearch) for 45 min at room
temperature. Mouse primary antibodies for Collagen-I (1:250, Cat. no. C2456, Sigma), Collagen-
1II (1:200, Cat. no. ab6310, Abcam), and Tenascin-C (1:250, Cat. no. ab88280, Abcam) were
added to respective wells and incubated overnight at 4'C. Goat anti-mouse Cy3 secondary
antibody (1:500, Cat. no. 115-165-062, Jackson ImmunoResearch) was added for 60 minutes at
room temperature. DAPI (1:500, Sigma) counterstain was added for 10 minutes at room
temperature. Images of each well were then obtained with an Olympus IX70 fluorescent
microscope equipped with an Olympus UM4-100 7A Cy3-710 fluorescent light filter, and a
SPOT digital camera and image processing software (Diagnostic Instruments). Orange coloring
in all images represents Cy3 staining.
Data analysis
Quantitative PCR was performed in triplicate per group per pig. Collagen I/ Collagen III
and Collagen I/ Tenascin-C ratios within each sample were calculated using relative expression
(2 -c"), since their primer efficiencies were all above 97%. No control genes were considered in
this case, as the calculation of a direct ratio does not need normalization. Statistical significance
was calculated using a student's T-test. P values <0.05 were considered significant.
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Table 3.1. Custom Pig Primer Sequences for Quantitative RT-PCR
Target Forward Sequence Reverse Sequence
Collagen-I 5'-CCTGGCTCTAGAGGTGAACG-3' 5'-AGGATTACCCACAGCACCAG-3'
Collagen-III 5'-TTGGCCCTGTTTGCTTTTA-3' 5'-TGGTTGACAAGATGAGAACAAAA-3'
Tenascin-C 5'-TTAAGTACGCGCCCATCTCT-3' 5'-CCTTCACAGCAGACACTCCA-3'
18s rRNA 5'-TCGCGGAAGGATTTAAAGTG-3' 5'-AAACGGCTACCACATCCAAG-3'
3.4. Results
Optimized primary ACL harvest
We find it important to note the difficulties we encountered in our initial attempts at
harvesting ACLc using previously published methodologies, and the subsequent improvements
we made to these protocols (21,130-132). First, we found that mincing the ACL tissue with
scissors in ACL DMEM resulted in an increased number of viable cells recovered as compared
to the published method of doing so in HBSS-- (data not shown). In addition, using only
collagenase was not sufficient for digestion if done for 2 hours or less, and if done for more than
2 hours it resulted in cell suspensions with low viability (<60%). The combination of collagenase
and dispase for 1 hour, as previously described by our laboratory for muscle tissue (134), yielded
a high-quantity of healthy fibroblasts (an average of 4x1 06 +/- 1.5x1 06 cells per I pig ACL with
90%+ viability) in a significantly smaller amount of time. Thus, we have established an
improved protocol for primary ACL cell isolation, where the midsubstance of a ligament is
cleaned of non-ligamentous tissue, minced in ACL DMEM and digested in a solution of 0.3%
Dispase-I and 1% Collagenase D for 60 minutes.
Cell characterization
The morphology of the ACLc isolated and used throughout the study is fibroblastic in
nature, as is typical of ACLc (Figure 3.1 A and 3.1 C). In addition, cells freshly isolated from
ACL tissue expressed ligament makers Collagen-1, Collagen-III and Tenascin-C, further
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characterizing them as ACL fibroblasts (Figure 3.2 D). MSCs isolated from bone marrow also
showed the expected fibroblastic morphology (Figure 3.1 B and 3.1 E), as well as the ability to
differentiate into osteogenic, adipogenic and chondrogenic lineages (Figure 3.2 A-C).
A
Figure 3.1. In vitro morphological characterization. (A) MSCs isolated from Pig bone marrow show
fibroblastic morphology. (B) ACL fibroblasts isolated from Pig ligament. Day-14 unstained cultures of
100% ACLcs (C), 50% ACLcs 50% MSCs, (D) and 100% MSCs (E). Scale bar = 100 rim. ACL, anterior
cruciate ligament; ACLcs, ACL cells; MSCs, mesenchymal stem cells.
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Figure 3.2. Fibroblast characterization. Pig MSCs differentiability to (A) adipogenic (scale bar = 25
Rm), (B) osteogenic (scale bar = 100 [tm), and (C) chondrogenic (scale bar = 100 Rm) lineages. (D)
Logio of the fold expression of ligament markers from freshly harvested ACL fibroblasts calibrated
with Pig hepatocytes.
Quantitative effect of co-culture on ligament marker expression
Results show that at day 14 the expression of Collagen-I was statistically similar across
cultures (p>0.05, Figure 3.3 A). At day 28 the 50% ACLc/50% MSCs sample was the only one
to show a significant increase in Collagen-I expression (p<0.02), and the level of Collagen-I
expression was significantly higher than any other culture group (p<0.01). Collagen-III
expression was significantly higher in the MSCs alone throughout the experiment (p<0.03), and
expression remained relatively constant across groups from 14 to 28 days (Figure 3.3 B). At 14
days, Tenascin-C expression was significantly higher (p<0.02) only in ACLc alone compared to
all other samples (Figure 3.3 C). By day 28, the 50% ACLc/50% MSCs sample was the only
group that showed a statistically significant increase in Tenascin-C expression (p<0.03).
Moreover, at 28 days ACLc alone and 50% ACLc/50% MSCs samples had significantly higher
Tenascin-C expression compared to all other samples (p<0.02), and the difference in their
expression at this time point was not statistically significant (p=0.4). Collagen-I to Collagen III
and Collagen-I to Tenascin-C expression ratios for all samples were compared to published
ratios for native ACL ligament (Figures 3.3 D and 3.3 E). In native ACL tissue, the Collagen-I to
Collagen-III ratio is approximately 9:1, while the Collagen-I to Tenascin-C ratio is greater than
15.7:1 (2-4,135). The highest ratio of Collagen-I to Collagen-III was observed in the 50% co-
culture group with a value of 5.8, while the lowest ratio was seen in the MSCs alone group at 0.8.
The 75% ACLc/25% MSCs had the second highest Collagen-I to Collagen-III ratio at 5.4,
however the overall expression of both markers in this group was markedly lower than the 50%
co-culture group throughout the experiment. For Collagen-I to Tenascin-C ratios, the highest
value was seen in the 25% ACLc/75% MSCs group at 6.5; while the lowest value was seen in
the ACLc alone group at 2.2, with the 50% co-culture group a close second at 3.2. Primer
efficiencies for qPCR gene expression analysis were 90.4% for 18s rRNA, 97.5% for Collagen-I,
97.6% for Collagen-IlI, and 98.7% for Tenascin-C.
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Figure 3.3. Fold expression of (A) Collagen-I, (B) Collagen- III, and (C) Tenascin-C at 14 and 28 days.
(D) Collagen-I- to-Collagen-III ratios for native ACL tissue and all co- culture conditions. (E) Collagen-I-
to-Tenascin-C ratios for native ACL tissue and all co-culture conditions. X-axis labels indicate
the %ACLcs/%MSCs ratio during co-culture. mRNA expression was detected using quantitative PCR and
normalized to 18s rRNA. For 100/0, 50/50, and 0/100, n=4, and all others n=3. * indicates statistically
significant increase with p < 0.05. Means - SD shown. Collagen-I, Collagen type I; Collagen-IlI,
Collagen type III.
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Extracellular matrix ligament marker expression
At 14 days, Collagen-I staining was similar across all samples (Figure 3.4 A); by day 28,
Collagen-I staining intensity was clearly increased in all samples, except in MSCs alone (Figure
3.5 A). At 14 days, Collagen-III staining was negligible in all samples (Figure 3.4 B); by day 28,
only the MSCs alone sample showed increased Collagen-III staining intensity (Figure 3.5 B). At
14 and 28 days, Tenascin-C staining was more intense in ACLc alone and 50% ACLc/50%
MSCs samples, while MSCs alone showed minimal Tenascin-C staining at both time points
(Figures 3.4 C and 3.5 C). Unstained day 14 cultures for ACLc alone, 50% ACLc/50% MSCs
and MSCs alone are shown in Figure 3.1 C-E. Native ACL tissue staining for the three markers
is shown in Figure 3.4 D.
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Figure 3.4. Ligament marker expression for (A) Collagen-I, (B) Collagen-III, and (C) Tenascin-C at 14
days. Column labels indicate the %ACLcs/%MSCs ratio during co-culture. (D) Native Pig ACL stains.
Orange coloring represents primary antibody, blue coloring represents nuclear stain. Scale bar = 100 [tm.
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Figure 3.5. Ligament marker expression for (A) Collagen-I, (B) Collagen-III, and (C) Tenascin-C at 28
days. Column labels indicate the %ACLcs/%MSCs ratio during co-culture. Orange coloring represents
primary antibody, blue coloring represents nuclear stain. Scale bar = 100 [rm.
3.5. Discussion
A key component of the successful creation of a tissue-engineered ligament is the source
of the cells from which regeneration is to occur. The goal of this study was to explore the effect
of direct co-culture of several ACLc/MSCs ratios on the overall expression of ligament markers.
Recent evidence suggests that co-culture systems may lead to enhanced regenerative responses,
especially when MSCs are involved (64,67,68,126,127,136). However, the majority if not all of
the studies focus on the differentiation potential of MSCs towards a specific lineage, and
disregard the plethora of additional benefits MSCs can provide to a regenerative response (70-
72). The ACL is a tissue that has limited regenerative potential, due in part to its restricted
vascular supply and also to its inability to form a functional healing bridge between the injured
or torn ends (7,11). Nevertheless, recent evidence suggests the tissue has the inherent capacity to
heal (80), with MSC-like progenitor cells readily available in the tissue, although this resource
must potentially be stimulated to induce a regenerative response.
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Our results show that a direct co-culture of ACLc and MSCs leads to increased
expression of ligament markers over 28 days. Collagen-I and Tenascin-C mRNA expression
increased over time in 50% co-culture compared to ACLc or MSCs cultured alone, suggesting
that in vitro extracellular matrix (ECM) formation of ACL cells may be enhanced in the presence
of MSCs. Immunofluorescent staining supported our mRNA observations, with Collagen-I
staining intensity becoming more widespread from 14 to 28 days, particularly in the ACLc and
50% co-culture groups; and Tenascin-C staining intensity increasing in ACLc alone and most
remarkably on 50% co-culture. Collagen-I is the marker that stains most prominently in native
pig ACL tissue, and the marker whose mRNA expression most remarkably increased when 50%
ACLc/50% MSCs were co-cultured. This observation becomes more notable when considering
that only half as many ACLc were seeded for the co-culture as compared to the ACLc alone
group. The control with ACLc cells seeded in a well at the 50% density without MSCs did not
show a Collagen-I expression response comparable to the 50% co-culture. In addition, Tenascin-
C mRNA expression significantly increased over 28 days in 50% co-culture, a response not
observed in any of the other groups. With the understanding that ECM deposition does not
always follow patterns of mRNA expression, our gene expression and immunofluorescence data
is complementary and suggests that MSCs in 1:1 co-culture with ACLc may enhance the
expression of Collagen-I and Tenascin-C.
An unanticipated result from our study was the finding that the MSCs alone culture
exhibited a significantly higher expression of Collagen-III throughout the experiment. Moreover,
our finding that Collagen-III expression in ACLc-containing cultures remained relatively
constant over time is consistent with previous reports (137). Collagen-III is a fibrillar component
of the extracellular matrix of ACL that is universally located throughout the ligament but is most
prominently found close to the attachment zones of the tissue (2,18). It comprises about 10% of
all collagen content, and plays a key role during the early phases of ligament healing and during
the ligamentization of tendon grafts undergoing remodeling after ACL reconstruction (2,115).
Collagen-Ill is known for its ability to make strengthening intermolecular disulfide crosslinks in
newly formed connective tissue ECM, and has been detected in high quantities at sites of injury
during the early phases of the healing response in bone, ligament, and tendon (135). These
responses during connective tissue healing may explain why we see MSCs alone as the group
with the highest expression of Collagen-III, since mesenchymal cells that differentiate into bone,
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cartilage and ligament cells tend to be the first to migrate to the injury sites of these tissues and
produce the early matrix of the reparative response (135). These observations about Collagen-III
suggest that MSCs could have a positive effect in healing during ACL regeneration. Perhaps, a
significant presence of MSCs in a construct aimed at ligament regeneration may have a greater
potential to initiate ligament healing and establish a structurally sound framework for the early
ECM, while a similar presence of ACLc may be required for long-term deposition of the
predominant and stronger Collagen-I. Taking all our conclusions into account, our results
suggest that utilizing a 50% co-culture of ACLc and MSCs in future ACL tissue engineering
studies may better maintain or enhance ligament ECM expression, and thus improve healing.
Native tissue studies have determined that about 90% of all collagen in ACL is type I,
while the remaining 10% is type III, yielding a 9:1 ratio of Collagen-I to Collagen-III (2-4). This
fact strengthens our conclusion that the 50% co-culture sample may be the best cell combination
in future tissue engineering studies of the ACL, since it exhibited the highest Collagen-I to
Collagen-III ratio of all samples at 5.8. Previous ligament healing studies have noted that, even
after long-term follow-up, the ligament scar found at a site of injury exhibited close to a 30%
decrease in normal collagen content and a significant increase in the relative amount of
Collagen-III content (135). Thus, a ratio lower than the native level of 9 should not be
unexpected in healing ligaments.
Tenascin-C is a glycoprotein found in tissues that experience high tensile and
compressive stresses, such as ligament and tendons, and it is involved in the binding of cell
surface receptors with the ECM (129). Even though its native levels in ACL tissue have not been
determined to our knowledge, it is part of the 6% of ligament components that are not a form of
collagen (94%) (2), making the true Collagen-I to Tenascin-C ratio in native ligament
significantly higher than 94:6. For this reason our analysis estimated this native ratio to be at
least 15. After tissue injury and during wound healing Tenascin-C levels have been shown to be
transiently overexpressed (138,139). Because of this, high levels of the marker are not expected
in native ligament tissue but are expected during a reparative response. Thus, the Collagen-I to
Tenascin-C ratio would be expected to be large in native ligament and low in instances of
ligament repair. Our mRNA analysis showed that the lowest ratios of Collagen-I to Tenascin-C
were observed in the ACLc and 50% co-culture groups, 2.2 and 3.2 respectively. This result
would imply that Tenascin-C is being overexpressed, which is expected in cells isolated from
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ACLc that may detect a state of "injury" and are mounting a healing response. This observation
also strengthens our support for the use of 50% co-cultures of ACLc and MSCs for tissue
engineering ACL attempts.
A co-culture of ACLc and MSCs may lead to an enhanced regenerative response in vivo
by providing not only a cell source from which cell differentiation can replenish an implanted
scaffold, but also by the production of chemokines and cytokines that promote angiogenesis
within the scaffolds, prevent scar formation, and awaken/recruit tissue-intrinsic progenitor cells
(ACL-derived MSCs) to the scaffold to increase the regeneration. Furthermore, MSCs anti-
inflammatory and immunomodulatory properties can provide a beneficial effect for biomaterial-
based implants (84,90). Many of the problems caused by biodegradable scaffolds implanted in
the body relate to the triggering of an immune response against the scaffold. MSCs could prevent
the immune response and decrease related inflammation at the site by their anti-inflammatory
effects, which in turn would protect the implant and enhance the repair. Ongoing studies in our
laboratory are examining this effect in 3D scaffold culture, as well as attempting to elucidate the
fate of MSCs in direct co-culture. An in vivo ACL regeneration model is also ongoing, where the
immunomodulatory and anti-inflammatory roles of MSCs are being more directly assessed.
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Chapter 4.
In vitro Development of Dynamic Three-Dimensional Co-Cultures of
Mesenchymal Stem Cells and Anterior Cruciate Ligament Cells for
Primary ACL Augmentation Repair
4.1. Rationale Behind 3D Co-Culture for Primary ACL Augmentation Repair
A nterior cruciate ligament (ACL) injuries are a common occurrence, particularly 
in athletes
participating in team sports. The literature suggests an incidence greater than 1 in 3500
ACL injuries per year in the general population (24). Over the past decade, yearly ACL injuries
and surgical reconstructions in the United States have been estimated at 200,000 and 100,000,
respectively (9,18,21,22,24). Although ACL reconstructions have had great success (9,29-31),
recent interest has shifted to the development of techniques that augment ruptured ACL and
permit a primary repair (10,11,38,140,141). The shift is based primarily in the desire to [1] spare
the remaining ligament innervation for proprioception at the knee joint, and [2] maintain the
local vascularization, all in an attempt to improve long-term outcomes (9,10,28,56,140-143).
After an ACL tears, the ligament stumps have a tendency to retract (56,141), and are
composed of inflamed and displaced tissue remnants (141,144). In order to perform a successful
primary repair, biologically enriched ligament augmentation devices are likely required for
success (11,140,141,145). Several groups have investigated the benefit of various biological
enhancers to primary repair techniques, including Platelet-Rich Plasma (PRP) with collagen
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sponges (11), and mesenchymal stem cell (MSCs) infiltration (10); however, the benefit of co-
culture systems for primary ACL repair augmentation has yet to be investigated. Recently, our
laboratory and others have shown that 1:1 co-cultures of MSC with primary ACL fibroblasts
(ACL cells, ACLcs) have a beneficial and enhancing effect in vitro on the expression of
ligament-associated markers and deposition of ligament extracellular matrix (97,99). Moreover,
it has been observed that seeding MSCs in aligned scaffolds with or without dynamic tensional
loading can stimulate MSC proliferation and differentiation towards a ligament lineage, with
increased overall extracellular matrix deposition and enhanced expression of ligament-associated
markers (146,147). Recent reports have shown that, in addition to promoting anti-inflammatory
and immunomodulatory processes, MSCs may create a regenerative atmosphere surrounding a
tissue injury that can enhance a healing response (70-75). Further, mononuclear cells including
MSCs have been shown to add beneficial effects to other primary repair techniques (98). With
these observations in mind, we wanted to explore the possibility of creating ligament
augmentation constructs from MSC and ACL fibroblast co-cultures in 3D cell-hydrogel-polymer
constructs. Our results in 2D suggest 1:1 co-cultures of MSCs and ACL fibroblasts may enhance
ligament tissue engineering (99), hence confirmation of these observations in 3D is warranted.
Incorporation of cells into a hydrogel matrix for tissue engineering has been extensively
investigated by our laboratory and others (124,148-152). One of the benefits of delivering cells
in hydrogel suspensions is the creation of a 3D extracellular matrix-like environment around the
cells that has been shown to help with the maintenance of cell phenotypes and the suitable
deposition of tissue-specific ECM (148,149,151,153-155). Additionally, delivering cell co-
cultures within a homogeneous hydrogel suspension allows for more uniform seeding of a solid
biomaterial scaffold, and prevents cell loss to the surrounding medium in vitro or neighboring
tissues in vivo (151,156-158). For our purposes, we selected a commercially available synthetic
hydrogel composed of thiol-modified sodium hyaluronate and gelatin cross-linked with
polyethylene glycol diacrylate (151,159). The hydrogel is stable in vitro, biocompatible, and has
shown promise in orthopaedic regenerative applications (151,160).
For successful primary ACL augmentation repair, a construct must have sufficient
mechanical stability to support joint function (44). To provide mechanical stability to our
ligament augmentation construct, the hydrogel suspension was seeded on a biodegradable
scaffold composed of a co-polymer of polyglycolic acid (PGA) and trimethylene carbonate
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(TMC), known as polyglyconate (PGA:TMC). PGA is a rigid and crystalline biodegradable
polymer used extensively in tissue engineering applications (124,152,161-166). It degrades
primarily via hydrolysis and has a degradation time of between 4 to 12 months, depending on
material configuration (164,166,167). TMC is a flexible, amorphous, non-acidic polycarbonate
that is stable to hydrolysis and mostly undergoes enzymatic degradation (161,164,166-168). The
block co-polymer PGA:TMC is FDA-approved and used commercially in MaxonTM sutures
(Covidien), SURETAC III fixation devices (Smith & Nephew), and as SEAMGUARD@
bioabsorbable staple line reinforcements and BIO-A® fistula plugs (W. L. Gore & Associates)
(161,166,167). Polyglyconate is a customizable biomaterial in terms of interconnecting porosity,
pore size, degradation rate and mechanical properties (161). It is also more biocompatible than
many alternative synthetic scaffolds, such as poly-L lactide (PLLA) or polyglycolide (PGA),
because of its decreased number of acid producing groups (161,167,169). Regarding degradation,
polyglyconate has an intermediate rate of degradation compared to PGA or PLLA, with a
degradation time of 6-12 months (161,165-167). This customizable biodegradation property,
dependent on the percent composition of PGA or TMC in the co-polymer (161,170), is attractive
for ligament augmentation, since the construct must be in place and functional long enough to
support mechanical loading, while allowing native tissue ingrowth, maturation and load transfer
to the regenerated ligament over time (171,172).
As tissue engineering began to be applied to ligament regeneration, investigators have
been interested in the effects of mechanical stimulation on cell behavior (173,174). Several
studies have observed the positive effect of mechanical tensional loads on ligament engineering,
including enhanced biomechanical properties, cell proliferation and differentiation, matrix
deposition and tissue orientation, among other benefits (68,69,146,173-184). In the present study
our intention was to subject the constructs to dynamic tensional loading conditions, previously
observed by others to be beneficial for ligament regeneration (173,177,178,183), to assess the
response of ACL cell-MSC co-cultures in three-dimensions. Our intent was to mimic in vitro the
active environment an augmentation construct would experience in vivo in a joint after
implantation. This multi-component approach using co-cultures, hydrogels and dynamically
loaded scaffolds is a feature that may allow our technique to succeed where others have failed
(10,11,40,52,57). Our objective was to determine the in vitro effects of the MSC-ACL cell co-
culture under dynamic tensional loading while seeded in three-dimensional constructs using
61
hydrogels as the cell delivery vehicle onto biodegradable and mechanically sound polymer
scaffolds. We hypothesized that the 3D co-culture constructs under tensional loading would
exhibit enhanced expression of ligament-associated markers. Our hope is to develop the
framework of a technique that can successfully allow the primary repair of ACL injuries off-the-
shelf and without the use of autografts or allografts.
4.2. Materials and Methods
Tissue harvest and cell isolation
ACL tissue and bone marrow were harvested from 6-8 month old Yorkshire pig legs
purchased from a local butcher house. The ACL fibroblasts (ACLcs) and MSCs were isolated as
previously described (99). Briefly, ACL tissue was aseptically dissected and washed in sterile
Hank's Buffered Salt Solution, Calcium and Magnesium free (HBSS--, Invitrogen). No. 21 blade
scalpels were used to gently scrape off synovial tissue from the surface of the ligament in a dish.
The tissue was transferred to a new dish with 10 ml of Dulbecco's Modified Eagle's Medium
(DMEM, Gibco) with 15% fetal bovine serum (FBS, Gibco), 1% L-glutamine (Gibco), and 1%
antibiotic mixture (Gibco) (ACL DMEM), and minced with scissors for 8-10 minutes until all
pieces were <1mm long axis length. Digestion of the tissue was performed in a solution of 2.4
U/ml Dispase-Il (Roche) and 10 mg/ml Collagenase D (Roche) for 60 min in a 37 0 C shaker. The
cell solution was filtered through a 100 [tm strainer (BD Falcon) and centrifuged at 260 g for 6
minutes. The cells obtained were resuspended in ACL DMEM and seeded at a density of 27x10 3
cells/cm 2 in T-75 tissue culture flasks (BD Falcon). Bone marrow was aspirated from the distal
femur of the same pig leg as previously described (124). Briefly, 3-5 ml of BM were aspirated
with a 16-gauge needle attached to a syringe with 0.5 ml sodium heparin (APP Pharmaceuticals),
diluted 1:9 in DMEM with 10% FBS and 1% antibiotic mixture (BM DMEM), and seeded in T-
75 flasks. Bone marrow-derived mesenchymal stem cells were isolated by their ability to attach
to tissue culture plastic (124).
Cells were passaged using 0.25% Trypsin/0.9 mM ethylenediaminetetraacetate (EDTA)
(Gibco) and seeded in 1:3 to 1:4 split ratios in T- 175 flasks (BD Falcon). All cells were grown to
passage 2. MSCs were not allowed to reach more than 60-70% confluency before passaging,
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while ACL cells were allowed to reach 80-90% confluency. Culture medium was changed twice
a week.
Biodegradable polymer scaffold
Scaffolds composed of self-cohered, aligned, non-woven fibers of 50% PGA:50% TMC
were provided by W.L. Gore & Associates. Supplier-reported polymer density was
approximately 8 mg/cm 2, fiber diameter ~30 tm, and porosity over 90% (Figure 4.1). 10 x 10
cm sheets with 1-2 mm thickness were sterilized by immersion in 70% ethanol for 20 min and
UV light irradiation for 15 min, and allowed to dry overnight. For ligament regeneration,
rectangular scaffolds were cut out of the sheet with the long axis of the rectangle along the
direction of fiber orientation.
Figure 4.1. 50%PGA:50% TMC Scaffold. (A) Scanning Electron Microscope image (X50). (B) Gross
appearance of unseeded, non-loaded scaffold. In both images fiber orientation is vertical.
Hydrogel reconstitution
ExtracelTM hydrogel (Glycosan Biosystems) was reconstituted per manufacturer's
protocol. Briefly, thiol-modified sodium hyaluronate, thiol-modified gelatin, and polyethylene
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glycol diacrylate (PEGDA) were allowed to thaw to room temperature. Aseptically, 1.0 mL of
degassed/deionized water was added to each, the hyaluronate and the gelatin, and allowed to
dissolve for 30 minutes at 37'C with gentle shaking. Reconstituted hyaluronate and gelatin
produced 1% (w/v) solutions. The clear, viscous solutions were mixed in equal volumes. The
PEGDA was reconstituted with 0.5 mL of sterile degassed/deionized water, making a 2% (w/v)
solution. Reconstituted PEGDA was immediately combined with the hyaluronate/gelatin mixture
in a 1:4 volume ratio, mixed well by pipetting, and immediately mixed with the respective cell
pellet. Within 5 minutes the cell-hydrogel liquid suspensions were seeded and adsorbed onto the
PGA:TMC scaffolds. Gelation occurred within 15 minutes. Reconstituted ExtracelTM has pH
~7.4 and a 0.4% w/v composition of thiol-modified hyaluronan and gelatin (159,185).
Scaffold seeding and dynamic culture
Passage 2 cells were collected using 0.25% Trypsin/0.9 mM EDTA, and viability
determined with the trypan-blue (Sigma) exclusion assay. MSCs and ACLcs (A-M) were
combined in 1:1 ratios in ACL DMEM and pelleted; pure ACLcs were also pelleted as a control.
Cell pellets were mixed with reconstituted ExtracelTM and micropipetted onto scaffolds at a
density of -50 million cell/cm 3 . The hydrogel:scaffold volume ratio was ~0.8 to prevent initial
hydrogel-cell suspension overflow from the scaffold. Upon gelation, within 15 minutes, the
scaffolds were transferred to well plates (BD Falcon) and ACL DMEM was added carefully to
prevent scaffold floating. A-M-seeded (co-cultured, n=15) and ACLcs-seeded (control, n=17)
scaffolds were cultured in static conditions in ACL DMEM at 37'C and 5% CO 2 for 21 days.
ACL DMEM medium was changed twice per week.
After 21 days, seven scaffolds of each seeding condition, A-M (n=7) and ACLcs (n=7),
previously loaded onto custom made interchangeable stainless steel clamps, were secured via
aluminum mounting block extensions onto a custom dynamic loading system that allows for
automated, cyclic, uniaxial tensile strains to be applied to ligament constructs while incubated in
nutritional media at 37'C (186) (Figure 4.2). Tensional loaded polymers were longer than
unloaded polymers to ensure clamped portion was not cell-seeded; care was taken to ensure the
polymer midsubstance (portion between clamps) had the same dimensions as all other samples
before adsorbing the cell-polymer suspension. As previously described for drug transport within
stretched muscle samples (186,187), the dynamic loading system has a LinMot@ P01-
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37x240/60x260 linear servo motor that drives the mechanical loading and can reach a peak force
of 72 N, velocity of 0.45 m/s, and acceleration of 8.5 m/s2 . The position of the motor is precisely
tracked by an internal sensor that has a 20 [tm resolution and is controlled by proportional-
integral-derivative logic enabling the execution of peak-to-peak displacements of 0.7 mm with
+/-60 [tm positional errors (186). Ligament constructs were cyclically loaded with 5% strain at
0.5 Hz for 60 minutes every other day for 7 days at 37'C in ACL DMEM. The loading regimen
was adapted from previously published reports of physiologically relevant strain environments
for ligament tissue engineering (146,177,178,180,183,184). When not under cyclic loading, the
samples were incubated at 37'C and 5% CO 2. Medium was changed after each loading cycle.
Static culture for these samples was 21 days, with a subsequent period of 7 days under
intermittent, cyclic tensional loading for a total culture time of 28 days.
The unloaded samples, A-M (n=8) and ACLcs (n=10), were maintained in static culture
at 37'C and 5% CO 2 for the same 7 days. Medium was changed every other day. Total static
culture time for these samples was 28 days.
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Figure 4.2. Uniaxial Tension Dynamic Loading System (186). (A) Linear motor for uniaxial tensional
loading. (B) Dynamic carriage for synchronized bilateral symmetric elongation. (C) Inferior view. (D)
Loading assembly with aluminum extensions and stainless steel clamps. (E) Stainless steel clamps with
ligament construct. (F) Secured polymer on dynamic loading assembly. (G) Ligament construct
submerged in media for cyclic loading. (H) Unseeded PGA:TMC polymer.
Quantitative reverse transcriptase-polymerase chain reaction
Expression of ligament-associated markers Collagen-I, Collagen-III and Tenascin-C was
quantified by real-time PCR as previously described (99). Briefly, total RNA was isolated from
co-cultured and control constructs with and without dynamic tensile loading (n=3 each) with an
RNeasy Plus Midi kit (Qiagen) per manufacturer's protocol using a tissue homogenizer (VWR).
1 [tg of total RNA per sample was reverse-transcribed in 20 [tl reactions using a High-Capacity
cDNA Reverse Transcription kit (Applied Biosystems) per manufacturer's specifications. Next,
2 1d of a 1:10 dilution of the reaction product was subjected to quantitative PCR using an iQ
SYBR Green Supermix kit in 20 [d reactions (Biorad). A C100 Thermal Cycler (Biorad) was
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used with the following program: 95'C 3 min, 1 cycle; 95 'C 10 sec -+ 64 'C 30 sec, repeat for
40 cycles total; 95 'C 10 sec -+ 65 'C 5 sec, 1 cycle. Previously published forward and reverse
gene-specific primers for Collagen-I, Collagen-Ill, Tenascin-C and 18s rRNA were used (Table
3.1)(99). Pig liver tissue was used as a negative control. 18s rRNA was used as the housekeeping
gene for normalization. Dissociation and amplification curve analysis was performed with the
Biorad CFX Manager software. Gene expression was obtained using the Pfaffl method to
account for individual reaction efficiencies using freshly harvested native ACL cells as the
calibrator sample (133).
Immunohistochemistry
Co-cultured constructs were fixed in 10% neutral buffered formalin (Sigma) overnight,
paraffin embedded and sectioned. Slides were treated with a 1:10 dilution of Target Retrieval
Solution (Dako) in distilled water for 10 min at 95-99'C. Non-specific blocking was performed
with Protein Block serum-free solution (Dako) for 30 min at room temperature. Mouse primary
antibodies for Collagen-I (1:200, Cat. no. C2456, Sigma), Collagen-III (1:100, Cat. no. ab63 10,
Abcam), and Tenascin-C (1:200, Cat. no. ab88280, Abcam) were added to respective slides and
incubated overnight at 4'C. Goat anti-mouse Cy3 secondary antibody (1:500, Cat. no. 115-165-
062, Jackson ImmunoResearch) was added for 60 minutes at room temperature. DAPI (1:500,
Sigma) counterstain was added for 10 minutes at room temperature. Images were obtained with
an Olympus IX70 fluorescent microscope equipped with an Olympus UM4-100 7A Cy3-710
fluorescent light filter, and a SPOT digital camera and image processing software (Diagnostic
Instruments).
Data analysis
Quantitative PCR was performed in triplicate per group. Collagen I/ Collagen III and
Collagen I/ Tenascin-C ratios within each sample were calculated using relative expression (2 -C)
since primer efficiencies were all above 97%. No control genes were considered in this case, as
the calculation of a direct ratio does not need normalization. Statistical significance was
calculated using a student's T-test. P values <0.05 were considered significant.
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4.3. Results
Quantitative effect of 3D-dynamically loaded co-cultures
After a period of 28 days of total culture, with 7 days of dynamic loading at 5% strain,
results show that loaded co-cultured constructs had significantly higher expression for all three
ligament-associated markers compared to unloaded constructs (Figure 4.3). Dynamic loading
significantly increased Collagen-I (p < 0.01, Fig. 4.3A), Collagen-III (p < 0.03, Fig. 4.3B), and
Tenascin-C (p < 0.03, Fig. 4.3C) expression in A-M constructs compared to non-loaded A-M
constructs. The ACLcs controls did not show a statistically significant difference between loaded
and unloaded samples (p > 0.05) for all markers. Within non-loaded samples, ACLcs constructs
had significantly increased expression compared to A-M constructs for Collagen-I (p < 0.03) and
Collagen-III (p < 0.04), but not Tenascin-C (p = 0.26). Interestingly, all marker expressions were
not statistically different among loaded A-M constructs and both, loaded and unloaded, ACLcs
constructs (p > 0.05), even though half as many ACLcs were seeded in the A-M scaffolds
compared to the ACLcs-only constructs.
Expression ratios between Collagen-I:Collagen-III, and Collagen-I:Tenascin-C were
compared to ratios obtained in the literature from native ACL (Fig. 4.3D, E). Native ACL has a
Collagen-I:Collagen-III ratio of 9:1, while the Collagen-I:Tenascin-C ratio is around 15:1 (2-
4,99,135). Our results show that loaded and unloaded A-M constructs had Collagen-I:Collagen-
III ratios of 8.8 and 10.4, respectively; while loaded and unloaded ACLcs construct ratios were
10.2 and 7.4, respectively. For Collagen-I:Tenascin-C, loaded and unloaded A-M constructs had
the lowest ratios at 5.9 and 6.0, respectively; whereas loaded and unloaded ACLcs constructs had
ratios of 8.2 and 11.4, respectively.
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Figure 4.3. Fold expression of 3D co-cultures. (A) Collagen-I, (B) Collagen-Ill, and (C) Tenascin-C at
28 days under static and dynamic conditions. (D) Collagen I/Collagen III ratios. (E) Collagen
I/Tenascin-C ratios. ACL/MSC cultures performed with a 1:1 ratio of each cell type at a density of 50
million cell/cm 3 . ACL cultures performed with only ACL fibroblasts at the same density. mRNA
expression was performed using quantitative PCR normalized with 18s rRNA. * indicates statistically
significant increase with p < 0.05. Means ± SD shown.
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Extracellular matrix deposition
Immunohistochemistry results showed that A-M co-cultured constructs had remarkably
increased staining intensity when dynamically loaded (Figure 4.4). For all three ligament-
associated markers, Collagen-I, Collagen-III and Tenascin-C, the intensity of the stain was
brighter and more abundant for A-M loaded samples.
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Figure 4.4. ACL/MSC construct marker expression. Collagen-I, (A) unloaded, (B) loaded; Collagen-III,
(C) unloaded, (D) loaded; Tenascin-C, (E) unloaded, (F) loaded. Scale bar = 100 stm.
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4.4. Discussion
The objective of the present study was to evaluate the effect of dynamically active
environments on the in vitro response of A-M co-cultures in three-dimensional polyglyconate-
hydrogel scaffolds. In order to develop ligament augmentation constructs that may be clinically
useful, in vitro studies must subject potential constructs to environments similar to what would
be experienced in the knee (188). Previous studies in our laboratory and others have shown that
direct co-cultures of ACLcs and MSCs have an enhancing effect on the expression and
deposition of ligament markers Collagen-I, Collagen-Ill and Tenascin-C (97,99). Before
proceeding to in vivo animal studies, our group wanted to confirm this observation in 3D, and
develop a potential construct for primary augmentation ligament repair.
Our results show that three-dimensional 1:1 A-M co-cultures under dynamic tensional
loading exhibit increased expression of ligament-associated markers. All three ligament markers,
Collagen-I, Collagen-III and Tenascin-C had statistically significant increases in expression over
28 days when compared to non-loaded co-cultured constructs. Notably, the loaded A-M
constructs did not show a significant difference in marker expression to the loaded and unloaded
ACLcs-only constructs, even though the A-M constructs had half as many ACLcs. As we have
shown before in 2D (99), this observation suggests that the interaction between ACLcs and
MSCs has an enhancing effect on the expression of the ligament-associated markers.
Immunohistochemical staining supported the mRNA results, with more intense and abundant
staining observed in loaded co-cultured constructs than unloaded samples. Taken together, these
observations suggests that in vitro ECM deposition by ACL cells is enhanced when co-cultured
with MSCs in three-dimensions, a result that supports our two-dimensional observations (99).
Thus, in future tissue engineering and regenerative medicine applications for ACL repair, the use
of 1:1 ACL cell-MSC co-cultures should be considered.
The 3D results observed in the current study directly follow the observations from our 2D
study (99), with the exception of the response seen for Collagen-Ill. In two dimensions, the only
group that exhibited significantly higher Collagen-Ill expression was the MSC-only cultures (99).
The significant difference was seen from the beginning, and there was no statistically significant
increase in Collagen-III expression from 2 to 4 weeks, even within MSC samples (99). In the
current three-dimensional study in hydrogel-polyglyconate scaffolds, the dynamically stretched
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A-M co-culture exhibited a statistically significant increase in Collagen-III expression when
compared to the unloaded sample. This positive result is akin to observations by other groups
studying 3D ACL and tendon regeneration (127,146,173,180), and 2D observations in ACL and
MSC co-cultures with and without mechanical stimulation (68,69,182).
Previously, we showed that Collagen-I and Tenascin-C expression could be enhanced
solely by direct contact 2D co-cultures of ACLcs and MSCs (99). During the present study, all
three markers exhibited the increase, Collagens-I and III, and Tenascin-C. The 3D/ECM-like
environment provided by the hydrogel and polyglyconate scaffold, combined with the dynamic
loading, appear to have had an enhancing effect on the ligament marker expression and
deposition, particularly for Collagen-Ill. Within tissue engineering, cell co-cultures in 3D
scaffolds have shown promise in terms of cell proliferation, differentiation and potential for
vascularization of the regenerated tissue (155). For ligament and tendon, hydrogel cell deliveries
have shown positive effects (47,62,189). Murray and colleagues have observed enhanced
ligament marker expression and matrix deposition, and improved biomechanical properties in
primary ACL repair enhanced with collagen-PRP hydrogels and scaffolds (11,42,43,47,98). Nuth
et al. also observed marker expression and deposition in Collagen type I hydrogels seeded with
MSCs for ACL repair (189). More recently, Freeman and colleagues used a polyethylene glycol
diacrylate-based hydrogel combined with PLLA to form ACL constructs (62). Their results
showed that the composites supported cell growth and had favorable protein release profiles that
can be used for future ACL repair (62). Analogously, a dynamic environment has been shown to
enhance ligament marker expression, including Collagen-III, particularly in three dimensions
(68,69,127,146,173,176,180,182). Thus, it is reasonable to conclude that the significant increase
of Collagen-III expression in our 3D scaffolds, not observed in 2D, was a synergistic result of the
three-dimensional and mechanically active environment.
Analyses of the Collagen-I/Collagen-II and Collagen-I/Tenascin-C ratios showed
responses suggestive of repair, and further support our conclusions. The Collagen-I/Collagen-Ill
ratios for ACL alone and co-culture samples, both loaded and unloaded, were at the level of that
observed in native ACL tissue, around 9:1 (2-4,99), suggesting an ECM deposition response
more similar to naturally three-dimensional native ligament. The Collagen-I/Tenascin-C ratios
were lowest and similar in the loaded and unloaded co-culture samples, both around 6:1 and far
from the 15:1 ratio observed in native ACL (2). This response is also anticipated, because
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Tenascin-C expression is transiently up-regulated during connective tissue healing responses
(138,139,190). Thus, the co-cultured samples exhibited Collagen-I/Tenascin-C ratios indicative
of proportional Tenascin-C overexpression, and suggestive of an improved reparative response
compared to ACL-only constructs. Interestingly, the Collagen-I/Tenascin-C ratio was moderately
lower in dynamically loaded ACL-alone constructs compared to unloaded ACL-alone constructs,
with ratios of 8.2 and 11.4, respectively. This observation in ACLcs-only samples further
suggests that dynamic stimulation improves the healing response of engineered ligaments, as
Tenascin-C was also proportionally overexpressed only under loading conditions, and is
consistent with previous ligament tissue engineering reports (68,69,127,173,176,180,182).
The choice of a hyaluronan-based hydrogel combined with a polyglyconate scaffold was
not deliberate. The use of hyaluronic acid for cartilage and ligament tissue engineering has been
well documented (11,149,151). Hyaluronan is a naturally-occurring glycosaminoglycan found in
a variety of tissues around the body, particularly connective tissues (149,151,191). It not only
plays a role in joint lubrication, but also in cell proliferation, cell regulation, cell differentiation,
as well as extracellular matrix modifications during development, injury and wound healing, and
immune/inflammatory responses (151,192,193). As it applies to ligament, intra-articular
hyaluronan injections have shown a positive effect during the healing of partial ACL tears in a
rabbit model, improving angiogenesis, decreasing inflammation and enhancing Collagen-III
synthesis when compared to saline controls (194). Furthermore, intra-articular delivery of
hyaluronan does not appear to cause detrimental or degenerative changes in ACL tissue (195),
and its use seems to be safe and beneficial in knee joint pathologies and procedures (196,197). In
terms of tissue engineering applications, Li and colleagues tested the effect of self-assembled
hyaluronic acid/gelatin coatings on polyethylene terephthalate ACL reconstruction grafts,
showing that the coating increased the synthetic material's biocompatibility by allowing better
cell adhesion and growth, and reducing inflammation (198). Their in vivo results showed that the
coating significantly reduced the inflammatory response to the implanted grafts and allowed for
neoligament regeneration with collagen deposition (198). Seo and colleagues tested a silk-
collagen-hyaluronan scaffold for ligament tissue engineering, and found that the collagen-
hyaluronan component improved angiogenesis and cell recruitment (199). The ExtracelTM
hydrogel used in our study has been shown to allow controlled release of growth factors, while
also allowing adequate infiltration and proliferation of cells (159). For cartilage tissue
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engineering, ExtracelTM has been shown to significantly increase total collagen content and
sulfated glycosaminoglycan retention (185). These observations motivated us to use a
hyaluronic-acid based hydrogel for the delivery of cell suspensions to the polymer, as it would
have a complementary positive effect within the knee joint when used in a primary augmentation
repair approach for ACL. Our overall positive results in terms of ligament matrix marker
expression and deposition support the use of the hydrogel for repair, although the particular
effect of the hyaluronan/gelatin hydrogel on cell behavior should be further explored.
Regarding the structural polymer choice, various biomaterials have been used in the past
with some success (reviewed in (22)). Particular success has been seen with PLLA and PLGA
scaffolds, but their long-term mechanical shortcomings, observed problems with tissue
integration, and overly slow degradation (57,146,200,201) motivated us to look for an alternative
material. The polyglyconate scaffold component was pursued as a structural stabilizer of a
potential primary augmentation ACL repair technique. Since polyglyconate is FDA-approved,
obstacles for its use in clinical applications are less compared to other materials. Previous
techniques in primary ACL repair have had relative success. Murray's bioenhanced augmented
primary repair has only been successful when performed immediately after ACL transection
(42); when the repair of ACL transection using the technique was delayed for 2 or 6 weeks, the
results were significantly adverse (52). As the investigators point out, a likely reason for the
bioenhanced technique failure is the stump retraction seen after ACL rupture (52,56). This
retraction is why a primary repair with augmentation can be a viable option. The benefits of
augmentation are well documented (66,140), and suture repair has shown mechanical
improvements in joint function after ACL injury (48). Thus, a combinatorial approach in which
our construct is used as an augmentation device in conjunction with a primary suture repair of a
ruptured ACL could be promising. The seeded construct would fill the gap between the retracted
stumps, serve as an enriched/regenerative bridge for cell, nerve and blood vessel migration
between the stumps, and provide initial stability to the joint in conjunction with the suture
(11,44). As previously established by Murray (44), bone-to-bone fixation with a suture would
still be needed to further stabilize the joint while regeneration is underway. Even during
rehabilitation the construct would be beneficial, as our current results and those of others show
that cyclic tensional loads similar to physiologic ranges enhance the regenerative response
(146,177,183,184,188). Polyglyconate is an ideal candidate as a scaffold, as it has shown
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excellent biocompatibility while having adjustable biodegradable and biomechanical properties
(161,170).
Recently, many groups have isolated MSC-like or adult stem cell-like cells directly from
ACL (80,81,115,202,203). Cheng and colleagues isolated a clonal population of ligament stem
cells by low seeding density expansion from ACL tissue (81,115). Their work shows that stem
cells from ligament have very similar properties to donor-matched BMSCs, and even argue that
ligament-derived stem cells have enhanced ligamentogenic properties compared to BMSCs
(81,115). Steinert et al. isolated what they describe as true MSCs from ACL, but in contrast to
Cheng, they conclude that ACL-derived MSCs have ligamentogenic properties comparable to
those of BMSCs (80). Mifune and group isolated CD34+ ligament vascular stem cells from ACL,
and though their properties are somewhat different to MSCs, they show potential for ligament
repair and even improvement for current ACL reconstruction techniques (202,203). Though the
evidence seems to suggest the existence of intrinsic stem cells in ACL, the inability for ACL to
mount a self-healing response is still unexplained (11,80). This is where co-culture may provide
a breakthrough. The regenerative potential of MSCs has been broadened by additional evidence
of their vast biologic behaviors: their trophic activity that helps with the generation of
vascularization, decreases scarring and fibrosis, and enhances tissue-intrinsic regenerative
responses (71,72,89); their immunomodulatory activity (74,75,90); and their plasticity
(72,77,79,82,83,85,86,88). Furthermore, several studies have shown the enhancing effects of co-
cultures between MSCs and other cell types, including ACL fibroblasts (64,67-69,99,126,127).
Our study in 2D (99) and the current results, combined with the additional attributes of MSC
biology (71,72), provide a potential framework for enhancing primary ACL repair by [1]
providing a source of stem cells (BMSCs) with ligamentogenic potential for differentiation, [2]
delivering a cell source (BMSCs) known to have regenerative, recruiting and anti-fibrotic
properties, and [3] a cell source (BMSCs) that can modulate the immune and inflammatory
responses existing in an injured ACL and that can be triggered in the body by foreign implants,
such as an ACL augmentation construct. The observation that dynamically loaded A-M
constructs experience a significant increase in ligament markers is supported by evidence
observed by other investigators (146), and backs the notion that co-culture with MSCs could
incite an intrinsic ACL reparative response.
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Murray and colleagues have also explored the potential benefits of mononuclear cell
(including lymphocytes, macrophages, monocytes and MSCs) supplementation of primary ACL
repair (97,98). They observed that 3D collagen constructs seeded with ACL fibroblasts and
supplemented with platelet-rich plasma and peripheral blood mononuclear cells increased the
expression of Collagen-I and Collagen-III after 14 days of culture (98). They further observed
that peripheral blood MSCs and adipose-derived MSCs in co-culture with ACL fibroblasts
enhanced cell migration, proliferation and ligament marker expression after 14 day cultures (97).
These observations support our previous results (99), as well as our 3D conclusions.
Nevertheless, in our opinion, the source of the MSCs should remain within the skeletal lineage.
Extensive reports support the notion that the preferred source of mesenchymal stem cells for
repair should be dependent on the targeted tissue, since MSCs from a particular source tend to
show behaviors similar to their origin, and an improved ability to regenerate tissue similar to its
source of origin (71,84,87,88,93,204). Xie and colleagues studied the effects of PRP on BMSC
and ADMSC chondrogenesis (205). Even though PRP did trigger a chondrogenic-like response
in both MSC sources, their results showed that BMSCs were superior in expressing
chondrogenic markers and generating hyaline-like cartilage, as the ADMSCs generated more
immature and fibrous tissue (205). These reports, along with the observation that even with
artificial growth factor supplementation ADMSCs do not exhibit a consistent and reliable ability
to regenerate ligament (92), support the use of BMSCs in future studies, as BMSCs have reliably
and consistently been differentiated into ligament (18,68,69,127,146,173,176,180,181), and
shown beneficial effects in terms of ligament regeneration (68,69,99,127,146,180).
In conclusion, our study shows that 3D hydrogel-scaffold constructs seeded with 1:1 co-
cultures of ACLcs and MSCs have an enhancing effect on the expression of genes for ligament
markers and the deposition of ligament ECM, especially under tensional loads. The next step in
our technique development is to assess the biochemical and mechanical response of the 3D
constructs in an in vivo animal model. Our hope is to establish a framework for a technique that
can allow the primary augmentation repair of ACL tears off-the-shelf, and without the need for
autografts or allografts.
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Chapter 5.
Summary and Future Directions
5.1. Thesis Summary
T he overall objective of this thesis is the establishment of a multi-component, combinatorial,tissue engineering framework for the development of a technique for primary augmentation
repair of ACL injuries. As outlined in Section 1.6, the experimental work of this thesis was based
on three specific aims.
Specific aim 1. Characterization of tibial mesenchymal stem cells. Hypothesize that proximal
tibial MSCs have the same differentiation potential as other bone marrow-derived MSCs.
As discussed in Chapter 2, human tibial bone marrow aspirates yielded MSCs that have
very similar properties to MSCs isolated from the iliac crest and other long bone sources.
Furthermore, the filter device for BMSC collection showed promise for use in future clinical
applications, as it will more quickly and efficiently deliver MSCs intraoperatively during
regenerative orthopaedic procedures. The detailed characterization of the tibial MSCs and the
positive differentiation results will allow our group to pursue in vivo animal studies and clinical
studies where MSCs can be harvested closer to the injury site, simplifying surgical procedures,
increasing patient comfort, and decreasing associated morbidities.
78
Specific aim 2. Characterization of the co-culture efjjcts ofprimary A CL fibroblasts and MSCs
in vitro. Hypothesize that co-culturing MSCs with ACL cells leads to an enhanced regenerative
response compared to either population alone.
Chapter 3 discussed extensively the behavior of ACLcs and MSCs in monolayer cultures.
We showed that during in vitro two dimensional culture, 1:1 ACLcs and MSC co-cultures
experience a significantly increased expression of Collagen type I and Tenascin-C markers, and a
Collagen-I/Collagen-III ratio closer to native ligament than other samples. The enhanced
response of the co-cultures in terms of ligament marker expression and matrix deposition
suggests that they may better preserve or even enhance ligament healing in potential orthopaedic
tissue engineering applications.
Specific aim 3. In vitro development of a construct jbr primary ACL augmentation repair with a
biodegradable scaffold based on poly(glycolic) acid: trimethylene carbonate (PGA:TMC)
combined with a hydrogel seeded with autologous MSCs and primary ACL fibroblasts under
dynamic tensile loading. Hypothesize that combining MSCs with primary ACL cells in a
hydrogel loaded in a biodegradable scaffold enhances the regenerative response, particularly in
tensile loading environments.
The discussion in Chapter 4 supports our 2D results in 3D environments, with co-cultures
exhibiting enhanced ligament marker expression and matrix deposition. Moreover, the dynamic
loading of 3D co-cultured samples with 1:1 ACLcs-MSC ratios resulted in significantly
increased Collagen-III expression, something not observed in 2D. Thus, in dynamic 3D, all three
ligament-associated markers had statistically significant increases in expression, an observation
that was corroborated by immunohistochemical data. These results allow our group to conclude
that for the development of a technique for primary ACL augmentation repair, the use of 3D co-
culture systems of ACLcs and MSCs can be beneficial, particularly when used in vivo, where the
constructs would experience dynamic tensional loadings during rehabilitation.
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5.2. Future Directions
The next step in the development of our ACL repair framework is the evaluation of 3D
co-cultured constructs in an in vivo animal model. Prior to pursuing a large animal model, we
explored the co-culture response in vivo in a preliminary study in a subcutaneous rodent model.
We implanted 1:1 Pig ACLcs:MSCs cell-hydrogel-scaffold constructs in subcutaneous pockets
of Nu/Nu mice for 3 months. As before, the scaffolds were seeded at a density of 50 million total
cells/cm3. ACL-only and MSC-only seeded constructs were also implanted as controls. To avoid
unexpected biocompatibility issues during the preliminary study, Pluronic@ F-127 was used as
the hydrogel. The hydrogel is similar to ExtracelTM, and our laboratory has more experience with
it in vitro and in vivo (150,206). The constructs were cultured in vitro at 37'C and 5% CO2 for 4
days prior to implantation. After 3 months in vivo, the implants were harvested, paraffin
embedded, sectioned and stained for all three ligament markers using immunohistochemistry.
The results were remarkably similar to what we observed in 2D and 3D in vitro cultures
(Figure 5.1). Collagen-I staining was similar and more intense in A-M and ACL-only samples,
whereas the MSC-only sample had practically no positive stain (Fig. 5.1A, D, G). Collagen-III
staining intensity was similar in all cell culture conditions, including MSC-only samples (Fig.
5.1B, E, H). Tenascin-C staining was noticeably more intense in A-M samples compared to
ACL-alone samples; MSC-only samples stained weakly positive for Tenascin-C (Fig. 5.1 C, F, I).
Although we understand that a subcutaneous, static environment is drastically different than an
intra-articular and dynamic environment, these preliminary results suggest that the co-culture
response observed in vitro could be reasonably expected to happen in vivo, prompting our
laboratory to consider a large animal model for ACL repair using our technique.
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Figure 5.1. Ligament marker expression of in vivo ACL constructs. Pig ACL cells and MSCs were
resuspended in Pluronic® F-127 hydrogel and seeded onto 50%PGA:50%TMC scaffolds. Three
conditions were examined: ACL-only seeded constructs (A, B, C); 1:1 ratio of ACL cells-MSCs (D, E,
F); MSC-only seeded constructs (G, H, I). Constructs were cultured in vitro for 4 days, then implanted in
subcutaneous pockets of Nu/Nu mice for 3 months. Upon harvest, constructs were stained with
immunohistochemistry for ligament markers Collagen-I (A, D, G), Collagen-III (B, E, H) and Tenascin-
C (C, F, I). Arrow points to location of positively stained matrix. Orange color represents Cy3 positive
stain for primary antibody. Blue color represents DAPI nuclear stain. Scale bar = 100 [im.
The ideal animal model for an ACL injury and repair is debatable (42,48,57,100).
Nevertheless, large animal models more closely resemble the environment experienced by an
ACL construct in a human knee (42,100). Consequently, our aim is to conduct an in vivo pig or
goat study of a delayed, full transection ACL injury model. The objective would be to use our
3D co-cultured cell-hydrogel-scaffold construct as an augmentation device to bridge the retracted
stumps of the ACL rupture, and evaluate the regenerated ligament with biochemical, histological
and biomechanical tools. In an in vivo model, the biomechanical properties of the construct post-
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implantation become critical, as applicability in humans would depend on the ability of the
implant to achieve mechanical stability in the joint close to, and preferably better than, current
graft reconstructions. The study would ideally evaluate constructs at 3, 6, and 12 months, with 6
animals at each time point for each study condition.
Conditions to explore during an in vivo study should include the choice of hydrogel with
which to deliver the cells in suspension to the polyglyconate scaffold. The ExtracelTM hydrogel,
based on hyaluronic acid and gelatin components, has shown positive results and good
biocompatibility in rabbit models of cartilage repair (160). Its ability to cross-link in situ, without
the need for temperature regulation or the addition of calcium ions, makes ExtracelTM preferable
for use in the operating room setting than more commonly used hydrogels, such as pluronic or
calcium alginate (151,159,160).
Platelet-rich formulations are also intriguing, as their rich growth factor and cytokine
content, as well as their anti-inflammatory and analgesic properties, appear to enhance healing of
sports injuries and increase the speed of recovery (207-209). Several groups have described these
various formulations and highlighted the benefits of using platelet-rich plasma (PRP) and/or
platelet-rich fibrin (PRF) in sports medicine and for orthopaedic injuries (207-213). Moreover,
the International Olympic Committee (IOC) recently published a consensus where the use of
PRP for athletic injuries is not considered a "performance enhancer", and its use is currently
permitted under IOC and World Anti-Doping Agency (WADA) regulations (214). For ACL
repair, Murray and colleagues have shown that PRP can enhance primary repairs of ACL (11,42).
Thus, it would be worth studying the effects of hydrogel enrichment with PRP on the
regenerative response of our constructs, or exploring the use of PRF hydrogels as the cell
delivery vehicle to the scaffold, instead of other hydrogels.
Another factor worth exploring in an in vivo model is whether dynamic tensional loading
of the ACL constructs prior to implantation is beneficial. Given that the results of our 3D study
showed that cyclic loads enhanced the expression of ligament markers and the deposition of
ECM, pre-conditioning a construct with dynamic loading before implantation may lead to better
tissue regeneration (215,216). On the other hand, pre-conditioning regiments would require in
vitro cultivation, a step that would increase the risk of contamination, delay the timing for repair,
and make more difficult any regulatory approval process for clinical use. Nevertheless, the effect
of pre-conditioning our constructs prior to implantation warrants study.
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Additionally, it would be interesting to evaluate in vivo whether ACL cells need to be
seeded with the MSCs directly on the scaffold before construct implantation. ACL cells have
been shown to migrate into various scaffolds, and MSCs have shown recruiting properties
towards ACL cells (97,217,218), therefore the implantation of MSC-seeded constructs may
trigger the migration of ACL cells into the construct from the augmented ligament stumps. This
would render our technique more easily introducible into a clinical setting by avoiding the need
to isolate ACL fibroblasts for scaffold seeding prior to implantation. Naturally, we would need to
determine if a sufficient number of ACL cells migrate into the scaffold in vivo, if any; and if the
ACL cell-MSC co-culture benefits reported in this thesis are still observed in such a "delayed co-
culture" approach. It is possible that not enough cells migrate in a timely fashion into the
scaffold, or that the delayed ACL cell-MSC ratio attained is not sufficient to trigger the observed
co-culture benefits.
Finally, even though the use of primary ACL cells and MSCs has shown promise,
exploring pioneering sources of cells for tissue regeneration would be desirable. Recently, our
laboratory has identified the presence and isolation method of adult tissue-derived pluripotent
stem cell clusters with the potential to differentiate across germ lines (219). These spheres are
composed of a heterogeneous population of cells, and unlike embryonic or induced pluripotent
stem cells, their pluripotency does not evoke ethical dilemmas, nor require genetic or
biochemical manipulations (219). Currently, we have started to explore their application for
tissue engineering, including cartilage and ligament; as well as their somatic plasticity under
stress environments (submitted manuscript). Perhaps their use in regenerative Orthopaedics will
one day spare the need to invasively harvest cells, and instead small blood or mucosal samples
would suffice to obtain cell sources for repair.
5.3. Glimpse Into the Future of ACL Repair
Our laboratory believes that there are three key requirements for an ideal, clinically
useful tissue-engineered ACL construct (220): [1] a cell harvest procedure that is easy and
minimally invasive, and yields sufficient cells for polymer seeding without the need for
extensive ex-vivo expansion; [2] a scaffold that is both biocompatible and biodegradable,
circumventing inflammatory responses from the host, and providing biomechanical support
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similar to that of native tissue until the ligament is regenerated; and [3] the ability of the implant
to continue to grow, especially when treating pediatric patients and young athletes. With these
points in mind, we developed the framework discussed throughout this thesis.
In the ideal future, an augmented primary ACL repair would be an arthroscopic, one-
stage procedure using intraoperatively harvested cells delivered in off-the-shelf products.
Possible approaches have been described by various investigators (28,140,141). In our vision, the
surgeon would arthroscopically harvest bone marrow with available kits, filter the marrow with
an MSC filter device similar to the one described in this thesis, and make a cell-hydrogel
suspension in the OR with a hydrogel. Standard length polymer scaffolds could then be cut to fit
the size of the patient and seeded with the cell-hydrogel suspension. An augmented primary ACL
repair would then be performed by connecting the remaining stumps using the scaffold and
sutures as a bridge. A bone-to-bone suture would then be added for mechanical stability as
previously described (44). This vision assumes that ACL fibroblasts would naturally, or with a
biological trigger, migrate out of the stumps into the scaffolding bridge, and an enhanced
regenerative response similar to the one observed in our studies would ensue (26,97,99,217,221).
A final thought about Sports Orthopaedics. Though surgical interventions, and soon
regenerative approaches, are often the best solution to orthopaedic injuries, the ultimate goal of
the field should be to develop means to better prevent injuries. Training programs that target the
prevention of injuries in athletes have shown a considerable reduction in the risk of ACL injury
(222), and should be further developed and implemented. The best treatment of an ACL injury is
preventing the injury from happening in the first place.
Tissue engineering and Regenerative Medicine is a relatively new field in science, with
its birth occurring somewhere around the mid-1980's (223-225). Despite numerous challenges
(223,224), the field has come a long way, with clinical trials ongoing for dermatologic,
orthopaedic, vascular, ophthalmologic, genitourinary and respiratory tissues (225). As
knowledge expands and new techniques are developed, organ regeneration in the clinic will
become commonplace. Even though we understand that the framework developed in this thesis is
far from becoming a clinical reality, we believe it represents the foundation and beginnings of a
technique with great potential.
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